id	sid	tid	token	lemma	pos
cana-5045	1	1	communications	communication	NOUN
cana-5045	1	2	on	on	ADP
cana-5045	1	3	applied	apply	VERB
cana-5045	1	4	nonlinear	nonlinear	ADJ
cana-5045	1	5	analysis	analysis	NOUN
cana-5045	1	6	issn	issn	NOUN
cana-5045	1	7	:	:	PUNCT
cana-5045	1	8	1074	1074	NUM
cana-5045	1	9	-	-	PUNCT
cana-5045	1	10	133x	133x	NUM
cana-5045	1	11	vol	vol	NOUN
cana-5045	1	12	32	32	NUM
cana-5045	1	13	no	no	NOUN
cana-5045	1	14	.	.	PUNCT
cana-5045	2	1	icmasd	icmasd	NOUN
cana-5045	2	2	(	(	PUNCT
cana-5045	2	3	2025	2025	NUM
cana-5045	2	4	)	)	PUNCT
cana-5045	2	5	174	174	NUM
cana-5045	2	6	https://internationalpubls.com	https://internationalpubls.com	X
cana-5045	2	7	the	the	DET
cana-5045	2	8	impact	impact	NOUN
cana-5045	2	9	of	of	ADP
cana-5045	2	10	sodium	sodium	NOUN
cana-5045	2	11	valproate	valproate	ADJ
cana-5045	2	12	on	on	ADP
cana-5045	2	13	male	male	ADJ
cana-5045	2	14	reproductive	reproductive	ADJ
cana-5045	2	15	health	health	NOUN
cana-5045	2	16	:	:	PUNCT
cana-5045	2	17	a	a	DET
cana-5045	2	18	comprehensive	comprehensive	ADJ
cana-5045	2	19	review	review	NOUN
cana-5045	2	20	harpreet	harpreet	ADV
cana-5045	2	21	singh1	singh1	PROPN
cana-5045	2	22	,	,	PUNCT
cana-5045	2	23	gaurav	gaurav	PROPN
cana-5045	2	24	verma1	verma1	PROPN
cana-5045	2	25	,	,	PUNCT
cana-5045	2	26	mohd	mohd	PROPN
cana-5045	2	27	.	.	PUNCT
cana-5045	3	1	shafi	shafi	PROPN
cana-5045	3	2	sheikh1	sheikh1	PROPN
cana-5045	3	3	1	1	NUM
cana-5045	3	4	ct	ct	PROPN
cana-5045	3	5	university	university	NOUN
cana-5045	3	6	,	,	PUNCT
cana-5045	3	7	ludhiana	ludhiana	PROPN
cana-5045	3	8	corresponding	correspond	VERB
cana-5045	3	9	author	author	NOUN
cana-5045	3	10	’s	’s	PART
cana-5045	3	11	email	email	NOUN
cana-5045	3	12	address	address	NOUN
cana-5045	3	13	:	:	PUNCT
cana-5045	3	14	harpreet24118@ctuniversity.in	harpreet24118@ctuniversity.in	NOUN
cana-5045	3	15	article	article	NOUN
cana-5045	3	16	history	history	NOUN
cana-5045	3	17	:	:	PUNCT
cana-5045	3	18	received	receive	VERB
cana-5045	3	19	:	:	PUNCT
cana-5045	3	20	12	12	NUM
cana-5045	3	21	-	-	SYM
cana-5045	3	22	11	11	NUM
cana-5045	3	23	-	-	PUNCT
cana-5045	3	24	2024	2024	NUM
cana-5045	3	25	revised	revise	VERB
cana-5045	3	26	:	:	PUNCT
cana-5045	3	27	25	25	NUM
cana-5045	3	28	-	-	SYM
cana-5045	3	29	12	12	NUM
cana-5045	3	30	-	-	PUNCT
cana-5045	3	31	2024	2024	NUM
cana-5045	3	32	accepted	accept	VERB
cana-5045	3	33	:	:	PUNCT
cana-5045	3	34	05	05	NUM
cana-5045	3	35	-	-	SYM
cana-5045	3	36	01	01	NUM
cana-5045	3	37	-	-	PUNCT
cana-5045	3	38	2025	2025	NUM
cana-5045	3	39	abstract	abstract	NOUN
cana-5045	3	40	:	:	PUNCT
cana-5045	3	41	sodium	sodium	NOUN
cana-5045	3	42	valproate	valproate	NOUN
cana-5045	3	43	is	be	AUX
cana-5045	3	44	one	one	NUM
cana-5045	3	45	of	of	ADP
cana-5045	3	46	the	the	DET
cana-5045	3	47	most	most	ADV
cana-5045	3	48	prescribed	prescribed	ADJ
cana-5045	3	49	antiepileptic	antiepileptic	ADJ
cana-5045	3	50	drugs	drug	NOUN
cana-5045	3	51	and	and	CCONJ
cana-5045	3	52	it	it	PRON
cana-5045	3	53	leads	lead	VERB
cana-5045	3	54	to	to	ADP
cana-5045	3	55	severe	severe	ADJ
cana-5045	3	56	reproductive	reproductive	ADJ
cana-5045	3	57	problems	problem	NOUN
cana-5045	3	58	among	among	ADP
cana-5045	3	59	men	man	NOUN
cana-5045	3	60	.	.	PUNCT
cana-5045	4	1	the	the	DET
cana-5045	4	2	objective	objective	NOUN
cana-5045	4	3	of	of	ADP
cana-5045	4	4	this	this	DET
cana-5045	4	5	review	review	NOUN
cana-5045	4	6	is	be	AUX
cana-5045	4	7	to	to	PART
cana-5045	4	8	provide	provide	VERB
cana-5045	4	9	an	an	DET
cana-5045	4	10	overview	overview	NOUN
cana-5045	4	11	about	about	ADP
cana-5045	4	12	the	the	DET
cana-5045	4	13	influence	influence	NOUN
cana-5045	4	14	of	of	ADP
cana-5045	4	15	valproate	valproate	NOUN
cana-5045	4	16	on	on	ADP
cana-5045	4	17	male	male	ADJ
cana-5045	4	18	fertility	fertility	NOUN
cana-5045	4	19	,	,	PUNCT
cana-5045	4	20	testicular	testicular	ADJ
cana-5045	4	21	morphology	morphology	NOUN
cana-5045	4	22	and	and	CCONJ
cana-5045	4	23	hormonal	hormonal	ADJ
cana-5045	4	24	regulation	regulation	NOUN
cana-5045	4	25	based	base	VERB
cana-5045	4	26	on	on	ADP
cana-5045	4	27	published	publish	VERB
cana-5045	4	28	data	datum	NOUN
cana-5045	4	29	.	.	PUNCT
cana-5045	5	1	several	several	ADJ
cana-5045	5	2	studies	study	NOUN
cana-5045	5	3	have	have	AUX
cana-5045	5	4	reported	report	VERB
cana-5045	5	5	that	that	SCONJ
cana-5045	5	6	chronic	chronic	ADJ
cana-5045	5	7	treatment	treatment	NOUN
cana-5045	5	8	with	with	ADP
cana-5045	5	9	valproic	valproic	ADJ
cana-5045	5	10	acid	acid	NOUN
cana-5045	5	11	can	can	AUX
cana-5045	5	12	cause	cause	VERB
cana-5045	5	13	testicular	testicular	ADJ
cana-5045	5	14	morphological	morphological	ADJ
cana-5045	5	15	alterations	alteration	NOUN
cana-5045	5	16	,	,	PUNCT
cana-5045	5	17	decreased	decrease	VERB
cana-5045	5	18	sperm	sperm	NOUN
cana-5045	5	19	mobility	mobility	NOUN
cana-5045	5	20	and	and	CCONJ
cana-5045	5	21	hormonal	hormonal	ADJ
cana-5045	5	22	imbalances	imbalance	NOUN
cana-5045	5	23	,	,	PUNCT
cana-5045	5	24	suggesting	suggest	VERB
cana-5045	5	25	male	male	ADJ
cana-5045	5	26	infertility	infertility	NOUN
cana-5045	5	27	.	.	PUNCT
cana-5045	6	1	research	research	NOUN
cana-5045	6	2	with	with	ADP
cana-5045	6	3	animal	animal	NOUN
cana-5045	6	4	models	model	NOUN
cana-5045	6	5	,	,	PUNCT
cana-5045	6	6	mostly	mostly	ADV
cana-5045	6	7	wistar	wistar	PROPN
cana-5045	6	8	rats	rat	NOUN
cana-5045	6	9	and	and	CCONJ
cana-5045	6	10	swiss	swiss	ADJ
cana-5045	6	11	mice	mouse	NOUN
cana-5045	6	12	,	,	PUNCT
cana-5045	6	13	has	have	AUX
cana-5045	6	14	demonstrated	demonstrate	VERB
cana-5045	6	15	that	that	SCONJ
cana-5045	6	16	valproate	valproate	ADJ
cana-5045	6	17	provokes	provoke	NOUN
cana-5045	6	18	germ	germ	NOUN
cana-5045	6	19	cell	cell	NOUN
cana-5045	6	20	damage	damage	NOUN
cana-5045	6	21	through	through	ADP
cana-5045	6	22	oxidative	oxidative	ADJ
cana-5045	6	23	stressgenotoxicity	stressgenotoxicity	NOUN
cana-5045	6	24	acted	act	VERB
cana-5045	6	25	induced	induce	VERB
cana-5045	6	26	meiosis	meiosis	NOUN
cana-5045	6	27	.	.	PUNCT
cana-5045	7	1	these	these	DET
cana-5045	7	2	findings	finding	NOUN
cana-5045	7	3	have	have	VERB
cana-5045	7	4	important	important	ADJ
cana-5045	7	5	implications	implication	NOUN
cana-5045	7	6	for	for	ADP
cana-5045	7	7	understanding	understand	VERB
cana-5045	7	8	the	the	DET
cana-5045	7	9	risks	risk	NOUN
cana-5045	7	10	of	of	ADP
cana-5045	7	11	valproate	valproate	ADJ
cana-5045	7	12	therapy	therapy	NOUN
cana-5045	7	13	in	in	ADP
cana-5045	7	14	epileptic	epileptic	ADJ
cana-5045	7	15	men	man	NOUN
cana-5045	7	16	.	.	PUNCT
cana-5045	8	1	it	it	PRON
cana-5045	8	2	also	also	ADV
cana-5045	8	3	reviews	review	VERB
cana-5045	8	4	other	other	ADJ
cana-5045	8	5	potential	potential	ADJ
cana-5045	8	6	preventive	preventive	ADJ
cana-5045	8	7	methods	method	NOUN
cana-5045	8	8	,	,	PUNCT
cana-5045	8	9	such	such	ADJ
cana-5045	8	10	as	as	ADP
cana-5045	8	11	antioxidant	antioxidant	ADJ
cana-5045	8	12	intervention	intervention	NOUN
cana-5045	8	13	that	that	PRON
cana-5045	8	14	would	would	AUX
cana-5045	8	15	decrease	decrease	VERB
cana-5045	8	16	the	the	DET
cana-5045	8	17	harmful	harmful	ADJ
cana-5045	8	18	effects	effect	NOUN
cana-5045	8	19	of	of	ADP
cana-5045	8	20	valproate	valproate	NOUN
cana-5045	8	21	on	on	ADP
cana-5045	8	22	reproductive	reproductive	ADJ
cana-5045	8	23	health	health	NOUN
cana-5045	8	24	.	.	PUNCT
cana-5045	9	1	collectively	collectively	ADV
cana-5045	9	2	,	,	PUNCT
cana-5045	9	3	the	the	DET
cana-5045	9	4	evidence	evidence	NOUN
cana-5045	9	5	presented	present	VERB
cana-5045	9	6	indicates	indicate	VERB
cana-5045	9	7	that	that	SCONJ
cana-5045	9	8	healthcare	healthcare	NOUN
cana-5045	9	9	providers	provider	NOUN
cana-5045	9	10	should	should	AUX
cana-5045	9	11	consider	consider	VERB
cana-5045	9	12	these	these	DET
cana-5045	9	13	risks	risk	NOUN
cana-5045	9	14	when	when	SCONJ
cana-5045	9	15	prescribing	prescribe	VERB
cana-5045	9	16	valproate	valproate	ADJ
cana-5045	9	17	and	and	CCONJ
cana-5045	9	18	investigate	investigate	VERB
cana-5045	9	19	alternative	alternative	ADJ
cana-5045	9	20	treatment	treatment	NOUN
cana-5045	9	21	options	option	NOUN
cana-5045	9	22	or	or	CCONJ
cana-5045	9	23	protective	protective	ADJ
cana-5045	9	24	measures	measure	NOUN
cana-5045	9	25	for	for	ADP
cana-5045	9	26	male	male	ADJ
cana-5045	9	27	patients	patient	NOUN
cana-5045	9	28	.	.	PUNCT
cana-5045	10	1	the	the	DET
cana-5045	10	2	purpose	purpose	NOUN
cana-5045	10	3	of	of	ADP
cana-5045	10	4	this	this	DET
cana-5045	10	5	comprehensive	comprehensive	ADJ
cana-5045	10	6	review	review	NOUN
cana-5045	10	7	is	be	AUX
cana-5045	10	8	to	to	PART
cana-5045	10	9	provide	provide	VERB
cana-5045	10	10	information	information	NOUN
cana-5045	10	11	regarding	regard	VERB
cana-5045	10	12	the	the	DET
cana-5045	10	13	clinical	clinical	ADJ
cana-5045	10	14	management	management	NOUN
cana-5045	10	15	and	and	CCONJ
cana-5045	10	16	also	also	ADV
cana-5045	10	17	indicates	indicate	VERB
cana-5045	10	18	future	future	ADJ
cana-5045	10	19	research	research	NOUN
cana-5045	10	20	prospects	prospect	NOUN
cana-5045	10	21	that	that	PRON
cana-5045	10	22	may	may	AUX
cana-5045	10	23	be	be	AUX
cana-5045	10	24	targeted	target	VERB
cana-5045	10	25	in	in	ADP
cana-5045	10	26	investigating	investigate	VERB
cana-5045	10	27	how	how	SCONJ
cana-5045	10	28	valproate	valproate	ADJ
cana-5045	10	29	use	use	NOUN
cana-5045	10	30	might	might	AUX
cana-5045	10	31	have	have	VERB
cana-5045	10	32	reproductive	reproductive	ADJ
cana-5045	10	33	consequences	consequence	NOUN
cana-5045	10	34	among	among	ADP
cana-5045	10	35	male	male	ADJ
cana-5045	10	36	population	population	NOUN
cana-5045	10	37	.	.	PUNCT
cana-5045	11	1	keywords	keyword	NOUN
cana-5045	11	2	:	:	PUNCT
cana-5045	11	3	valproate	valproate	ADJ
cana-5045	11	4	,	,	PUNCT
cana-5045	11	5	male	male	ADJ
cana-5045	11	6	fertility	fertility	NOUN
cana-5045	11	7	,	,	PUNCT
cana-5045	11	8	reproductive	reproductive	ADJ
cana-5045	11	9	health	health	NOUN
cana-5045	11	10	1	1	NUM
cana-5045	11	11	.	.	PUNCT
cana-5045	12	1	introduction	introduction	NOUN
cana-5045	12	2	valproate	valproate	ADJ
cana-5045	12	3	(	(	PUNCT
cana-5045	12	4	sodium	sodium	NOUN
cana-5045	12	5	valproate	valproate	NOUN
cana-5045	12	6	)	)	PUNCT
cana-5045	12	7	is	be	AUX
cana-5045	12	8	also	also	ADV
cana-5045	12	9	a	a	DET
cana-5045	12	10	medication	medication	NOUN
cana-5045	12	11	used	use	VERB
cana-5045	12	12	in	in	ADP
cana-5045	12	13	the	the	DET
cana-5045	12	14	treatment	treatment	NOUN
cana-5045	12	15	of	of	ADP
cana-5045	12	16	epilepsy	epilepsy	NOUN
cana-5045	12	17	,	,	PUNCT
cana-5045	12	18	bipolar	bipolar	ADJ
cana-5045	12	19	disorder	disorder	NOUN
cana-5045	12	20	and	and	CCONJ
cana-5045	12	21	migraine	migraine	NOUN
cana-5045	12	22	headaches(iamsaard	headaches(iamsaard	PROPN
cana-5045	12	23	et	et	PROPN
cana-5045	12	24	al	al	PROPN
cana-5045	12	25	.	.	PROPN
cana-5045	12	26	2017	2017	NUM
cana-5045	12	27	)	)	PUNCT
cana-5045	12	28	.	.	PUNCT
cana-5045	13	1	it	it	PRON
cana-5045	13	2	was	be	AUX
cana-5045	13	3	established	establish	VERB
cana-5045	13	4	in	in	ADP
cana-5045	13	5	the	the	DET
cana-5045	13	6	1960s	1960	NOUN
cana-5045	13	7	and	and	CCONJ
cana-5045	13	8	has	have	AUX
cana-5045	13	9	since	since	ADV
cana-5045	13	10	been	be	AUX
cana-5045	13	11	widely	widely	ADV
cana-5045	13	12	used	use	VERB
cana-5045	13	13	for	for	ADP
cana-5045	13	14	the	the	DET
cana-5045	13	15	treatment	treatment	NOUN
cana-5045	13	16	of	of	ADP
cana-5045	13	17	seizures	seizure	NOUN
cana-5045	13	18	,	,	PUNCT
cana-5045	13	19	especially	especially	ADV
cana-5045	13	20	when	when	SCONJ
cana-5045	13	21	patients	patient	NOUN
cana-5045	13	22	are	be	AUX
cana-5045	13	23	resistant	resistant	ADJ
cana-5045	13	24	to	to	ADP
cana-5045	13	25	other	other	ADJ
cana-5045	13	26	anti	anti	ADJ
cana-5045	13	27	-	-	ADJ
cana-5045	13	28	epileptic	epileptic	ADJ
cana-5045	13	29	drugs(perucca	drugs(perucca	ADJ
cana-5045	13	30	2012	2012	NUM
cana-5045	13	31	)	)	PUNCT
cana-5045	13	32	.	.	PUNCT
cana-5045	14	1	although	although	SCONJ
cana-5045	14	2	valproate	valproate	ADJ
cana-5045	14	3	exhibits	exhibit	VERB
cana-5045	14	4	therapeutic	therapeutic	ADJ
cana-5045	14	5	properties	property	NOUN
cana-5045	14	6	,	,	PUNCT
cana-5045	14	7	there	there	PRON
cana-5045	14	8	are	be	VERB
cana-5045	14	9	concerns	concern	NOUN
cana-5045	14	10	about	about	ADP
cana-5045	14	11	its	its	PRON
cana-5045	14	12	detrimental	detrimental	ADJ
cana-5045	14	13	impacts	impact	NOUN
cana-5045	14	14	on	on	ADP
cana-5045	14	15	male	male	ADJ
cana-5045	14	16	reproductive	reproductive	ADJ
cana-5045	14	17	health	health	NOUN
cana-5045	14	18	.	.	PUNCT
cana-5045	15	1	more	more	ADJ
cana-5045	15	2	research	research	NOUN
cana-5045	15	3	is	be	AUX
cana-5045	15	4	being	be	AUX
cana-5045	15	5	dedicated	dedicate	VERB
cana-5045	15	6	to	to	PART
cana-5045	15	7	identify	identify	VERB
cana-5045	15	8	what	what	PRON
cana-5045	15	9	effects	effect	NOUN
cana-5045	15	10	valproic	valproic	ADJ
cana-5045	15	11	acid	acid	NOUN
cana-5045	15	12	has	have	VERB
cana-5045	15	13	on	on	ADP
cana-5045	15	14	male	male	ADJ
cana-5045	15	15	fertility	fertility	NOUN
cana-5045	15	16	and	and	CCONJ
cana-5045	15	17	hormonal	hormonal	ADJ
cana-5045	15	18	profile	profile	NOUN
cana-5045	15	19	over	over	ADP
cana-5045	15	20	long	long	ADJ
cana-5045	15	21	term	term	NOUN
cana-5045	15	22	administration(romoli	administration(romoli	PROPN
cana-5045	15	23	et	et	NOUN
cana-5045	15	24	al	al	PROPN
cana-5045	15	25	.	.	PROPN
cana-5045	15	26	2019	2019	NUM
cana-5045	15	27	)	)	PUNCT
cana-5045	15	28	.	.	PUNCT
cana-5045	16	1	the	the	DET
cana-5045	16	2	male	male	ADJ
cana-5045	16	3	reproductive	reproductive	ADJ
cana-5045	16	4	system	system	NOUN
cana-5045	16	5	is	be	AUX
cana-5045	16	6	highly	highly	ADV
cana-5045	16	7	sensitive	sensitive	ADJ
cana-5045	16	8	to	to	ADP
cana-5045	16	9	different	different	ADJ
cana-5045	16	10	environmental	environmental	ADJ
cana-5045	16	11	and	and	CCONJ
cana-5045	16	12	pharmacological	pharmacological	ADJ
cana-5045	16	13	agents	agent	NOUN
cana-5045	16	14	,	,	PUNCT
cana-5045	16	15	and	and	CCONJ
cana-5045	16	16	the	the	DET
cana-5045	16	17	effect	effect	NOUN
cana-5045	16	18	of	of	ADP
cana-5045	16	19	drugs	drug	NOUN
cana-5045	16	20	like	like	ADP
cana-5045	16	21	valproate	valproate	NOUN
cana-5045	16	22	can	can	AUX
cana-5045	16	23	be	be	AUX
cana-5045	16	24	profound(mascarenhas	profound(mascarenhas	PROPN
cana-5045	16	25	,	,	PUNCT
cana-5045	16	26	sousa	sousa	NOUN
cana-5045	16	27	,	,	PUNCT
cana-5045	16	28	and	and	CCONJ
cana-5045	16	29	rato	rato	PROPN
cana-5045	16	30	2024	2024	NUM
cana-5045	16	31	)	)	PUNCT
cana-5045	16	32	.	.	PUNCT
cana-5045	17	1	research	research	NOUN
cana-5045	17	2	demonstrates	demonstrate	VERB
cana-5045	17	3	that	that	SCONJ
cana-5045	17	4	males	male	NOUN
cana-5045	17	5	who	who	PRON
cana-5045	17	6	receive	receive	VERB
cana-5045	17	7	valproate	valproate	ADJ
cana-5045	17	8	as	as	ADP
cana-5045	17	9	a	a	DET
cana-5045	17	10	treatment	treatment	NOUN
cana-5045	17	11	often	often	ADV
cana-5045	17	12	suffer	suffer	VERB
cana-5045	17	13	from	from	ADP
cana-5045	17	14	reproductive	reproductive	ADJ
cana-5045	17	15	problems	problem	NOUN
cana-5045	17	16	,	,	PUNCT
cana-5045	17	17	such	such	ADJ
cana-5045	17	18	as	as	ADP
cana-5045	17	19	changes	change	NOUN
cana-5045	17	20	in	in	ADP
cana-5045	17	21	epididymal	epididymal	ADJ
cana-5045	17	22	structure	structure	NOUN
cana-5045	17	23	and	and	CCONJ
cana-5045	17	24	these	these	DET
cana-5045	17	25	factors	factor	NOUN
cana-5045	17	26	may	may	AUX
cana-5045	17	27	be	be	AUX
cana-5045	17	28	employed	employ	VERB
cana-5045	17	29	for	for	ADP
cana-5045	17	30	the	the	DET
cana-5045	17	31	prediction	prediction	NOUN
cana-5045	17	32	of	of	ADP
cana-5045	17	33	decreased	decrease	VERB
cana-5045	17	34	sperm	sperm	NOUN
cana-5045	17	35	count	count	NOUN
cana-5045	17	36	.	.	PUNCT
cana-5045	18	1	for	for	ADP
cana-5045	18	2	instance	instance	NOUN
cana-5045	18	3	,	,	PUNCT
cana-5045	18	4	studied	study	VERB
cana-5045	18	5	male	male	ADJ
cana-5045	18	6	wistar	wistar	PROPN
cana-5045	18	7	rats	rat	NOUN
cana-5045	18	8	and	and	CCONJ
cana-5045	18	9	reported	report	VERB
cana-5045	18	10	communications	communication	NOUN
cana-5045	18	11	on	on	ADP
cana-5045	18	12	applied	apply	VERB
cana-5045	18	13	nonlinear	nonlinear	ADJ
cana-5045	18	14	analysis	analysis	NOUN
cana-5045	18	15	issn	issn	NOUN
cana-5045	18	16	:	:	PUNCT
cana-5045	18	17	1074	1074	NUM
cana-5045	18	18	-	-	PUNCT
cana-5045	18	19	133x	133x	NUM
cana-5045	18	20	vol	vol	NOUN
cana-5045	18	21	32	32	NUM
cana-5045	18	22	no	no	NOUN
cana-5045	18	23	.	.	PUNCT
cana-5045	19	1	icmasd	icmasd	NOUN
cana-5045	19	2	(	(	PUNCT
cana-5045	19	3	2025	2025	NUM
cana-5045	19	4	)	)	PUNCT
cana-5045	19	5	175	175	NUM
cana-5045	19	6	https://internationalpubls.com	https://internationalpubls.com	NUM
cana-5045	19	7	marked	mark	VERB
cana-5045	19	8	histopathological	histopathological	ADJ
cana-5045	19	9	changes	change	NOUN
cana-5045	19	10	in	in	ADP
cana-5045	19	11	the	the	DET
cana-5045	19	12	testes	testis	NOUN
cana-5045	19	13	after	after	ADP
cana-5045	19	14	long	long	ADJ
cana-5045	19	15	-	-	PUNCT
cana-5045	19	16	term	term	NOUN
cana-5045	19	17	treatment	treatment	NOUN
cana-5045	19	18	with	with	ADP
cana-5045	19	19	valproate	valproate	ADJ
cana-5045	19	20	,	,	PUNCT
cana-5045	19	21	indicative	indicative	ADJ
cana-5045	19	22	of	of	ADP
cana-5045	19	23	morphological	morphological	ADJ
cana-5045	19	24	structural	structural	ADJ
cana-5045	19	25	alterations	alteration	NOUN
cana-5045	19	26	within	within	ADP
cana-5045	19	27	the	the	DET
cana-5045	19	28	organ(røste	organ(røste	PROPN
cana-5045	19	29	et	et	PROPN
cana-5045	19	30	al	al	PROPN
cana-5045	19	31	.	.	PROPN
cana-5045	19	32	2001	2001	NUM
cana-5045	19	33	)	)	PUNCT
cana-5045	19	34	.	.	PUNCT
cana-5045	20	1	the	the	DET
cana-5045	20	2	changes	change	NOUN
cana-5045	20	3	in	in	ADP
cana-5045	20	4	fertility	fertility	NOUN
cana-5045	20	5	were	be	AUX
cana-5045	20	6	associated	associate	VERB
cana-5045	20	7	with	with	ADP
cana-5045	20	8	a	a	DET
cana-5045	20	9	decreased	decrease	VERB
cana-5045	20	10	sperm	sperm	NOUN
cana-5045	20	11	count	count	NOUN
cana-5045	20	12	and	and	CCONJ
cana-5045	20	13	motility	motility	NOUN
cana-5045	20	14	,	,	PUNCT
cana-5045	20	15	implicating	implicate	VERB
cana-5045	20	16	valproate	valproate	ADJ
cana-5045	20	17	exposure	exposure	NOUN
cana-5045	20	18	as	as	ADP
cana-5045	20	19	being	be	AUX
cana-5045	20	20	directly	directly	ADV
cana-5045	20	21	responsible	responsible	ADJ
cana-5045	20	22	for	for	ADP
cana-5045	20	23	impaired	impaired	ADJ
cana-5045	20	24	fertility(tallon	fertility(tallon	NOUN
cana-5045	20	25	,	,	PUNCT
cana-5045	20	26	o’donovan	o’donovan	NOUN
cana-5045	20	27	,	,	PUNCT
cana-5045	20	28	and	and	CCONJ
cana-5045	20	29	delanty	delanty	NOUN
cana-5045	20	30	2021	2021	NUM
cana-5045	20	31	)	)	PUNCT
cana-5045	20	32	.	.	PUNCT
cana-5045	21	1	valproate	valproate	ADJ
cana-5045	21	2	impairs	impair	VERB
cana-5045	21	3	male	male	ADJ
cana-5045	21	4	reproductive	reproductive	ADJ
cana-5045	21	5	health	health	NOUN
cana-5045	21	6	both	both	CCONJ
cana-5045	21	7	directly	directly	ADV
cana-5045	21	8	and	and	CCONJ
cana-5045	21	9	indirectly	indirectly	ADV
cana-5045	21	10	through	through	ADP
cana-5045	21	11	multiple	multiple	ADJ
cana-5045	21	12	mechanisms	mechanism	NOUN
cana-5045	21	13	.	.	PUNCT
cana-5045	22	1	one	one	NUM
cana-5045	22	2	of	of	ADP
cana-5045	22	3	the	the	DET
cana-5045	22	4	suggested	suggest	VERB
cana-5045	22	5	mechanisms	mechanism	NOUN
cana-5045	22	6	is	be	AUX
cana-5045	22	7	oxidative	oxidative	ADJ
cana-5045	22	8	stress	stress	NOUN
cana-5045	22	9	,	,	PUNCT
cana-5045	22	10	that	that	SCONJ
cana-5045	22	11	when	when	SCONJ
cana-5045	22	12	there	there	PRON
cana-5045	22	13	are	be	VERB
cana-5045	22	14	more	more	ADV
cana-5045	22	15	reactive	reactive	ADJ
cana-5045	22	16	oxygen	oxygen	NOUN
cana-5045	22	17	species	specie	NOUN
cana-5045	22	18	(	(	PUNCT
cana-5045	22	19	ros	ros	PROPN
cana-5045	22	20	)	)	PUNCT
cana-5045	22	21	than	than	ADP
cana-5045	22	22	antioxidant	antioxidant	ADJ
cana-5045	22	23	defenses(walke	defenses(walke	PROPN
cana-5045	22	24	et	et	NOUN
cana-5045	22	25	al	al	PROPN
cana-5045	22	26	.	.	PROPN
cana-5045	22	27	2023	2023	NUM
cana-5045	22	28	)	)	PUNCT
cana-5045	22	29	.	.	PUNCT
cana-5045	23	1	high	high	ADJ
cana-5045	23	2	levels	level	NOUN
cana-5045	23	3	of	of	ADP
cana-5045	23	4	oxidative	oxidative	ADJ
cana-5045	23	5	stress	stress	NOUN
cana-5045	23	6	creates	create	VERB
cana-5045	23	7	cellular	cellular	ADJ
cana-5045	23	8	damage	damage	NOUN
cana-5045	23	9	,	,	PUNCT
cana-5045	23	10	through	through	ADP
cana-5045	23	11	dna	dna	PROPN
cana-5045	23	12	fragmentation	fragmentation	NOUN
cana-5045	23	13	and	and	CCONJ
cana-5045	23	14	apoptosis	apoptosis	NOUN
cana-5045	23	15	of	of	ADP
cana-5045	23	16	germ	germ	NOUN
cana-5045	23	17	cells	cell	NOUN
cana-5045	23	18	.	.	PUNCT
cana-5045	24	1	in	in	ADP
cana-5045	24	2	male	male	ADJ
cana-5045	24	3	mice	mouse	NOUN
cana-5045	24	4	,	,	PUNCT
cana-5045	24	5	sodium	sodium	NOUN
cana-5045	24	6	valproate	valproate	ADJ
cana-5045	24	7	induced	induce	VERB
cana-5045	24	8	oxidative	oxidative	ADJ
cana-5045	24	9	damage	damage	NOUN
cana-5045	24	10	again	again	ADV
cana-5045	24	11	supports	support	VERB
cana-5045	24	12	the	the	DET
cana-5045	24	13	hypothesis	hypothesis	NOUN
cana-5045	24	14	that	that	PRON
cana-5045	24	15	the	the	DET
cana-5045	24	16	reproductive	reproductive	ADJ
cana-5045	24	17	toxicity	toxicity	NOUN
cana-5045	24	18	of	of	ADP
cana-5045	24	19	this	this	DET
cana-5045	24	20	drug	drug	NOUN
cana-5045	24	21	may	may	AUX
cana-5045	24	22	occur	occur	VERB
cana-5045	24	23	via	via	ADP
cana-5045	24	24	induction	induction	NOUN
cana-5045	24	25	of	of	ADP
cana-5045	24	26	an	an	DET
cana-5045	24	27	oxidizing	oxidizing	NOUN
cana-5045	24	28	state(khan	state(khan	PROPN
cana-5045	24	29	et	et	PROPN
cana-5045	24	30	al	al	PROPN
cana-5045	24	31	.	.	PROPN
cana-5045	24	32	2011	2011	NUM
cana-5045	24	33	)	)	PUNCT
cana-5045	24	34	.	.	PUNCT
cana-5045	25	1	valproate	valproate	ADJ
cana-5045	25	2	treatment	treatment	NOUN
cana-5045	25	3	can	can	AUX
cana-5045	25	4	also	also	ADV
cana-5045	25	5	worsen	worsen	VERB
cana-5045	25	6	these	these	DET
cana-5045	25	7	effects	effect	NOUN
cana-5045	25	8	,	,	PUNCT
cana-5045	25	9	possibly	possibly	ADV
cana-5045	25	10	through	through	ADP
cana-5045	25	11	a	a	DET
cana-5045	25	12	synergistic	synergistic	ADJ
cana-5045	25	13	effect	effect	NOUN
cana-5045	25	14	of	of	ADP
cana-5045	25	15	valproate	valproate	NOUN
cana-5045	25	16	on	on	ADP
cana-5045	25	17	any	any	DET
cana-5045	25	18	hormonal	hormonal	ADJ
cana-5045	25	19	imbalances(svalheim	imbalances(svalheim	PROPN
cana-5045	25	20	et	et	PROPN
cana-5045	25	21	al	al	PROPN
cana-5045	25	22	.	.	PROPN
cana-5045	25	23	2015	2015	NUM
cana-5045	25	24	)	)	PUNCT
cana-5045	25	25	.	.	PUNCT
cana-5045	26	1	men	man	NOUN
cana-5045	26	2	with	with	ADP
cana-5045	26	3	epilepsy	epilepsy	NOUN
cana-5045	26	4	receiving	receive	VERB
cana-5045	26	5	valproate	valproate	ADJ
cana-5045	26	6	show	show	NOUN
cana-5045	26	7	changes	change	NOUN
cana-5045	26	8	in	in	ADP
cana-5045	26	9	reproductive	reproductive	ADJ
cana-5045	26	10	hormones	hormone	NOUN
cana-5045	26	11	,	,	PUNCT
cana-5045	26	12	including	include	VERB
cana-5045	26	13	reductions	reduction	NOUN
cana-5045	26	14	in	in	ADP
cana-5045	26	15	testosterone	testosterone	NOUN
cana-5045	26	16	levels	level	NOUN
cana-5045	26	17	,	,	PUNCT
cana-5045	26	18	an	an	DET
cana-5045	26	19	essential	essential	ADJ
cana-5045	26	20	factor	factor	NOUN
cana-5045	26	21	for	for	ADP
cana-5045	26	22	both	both	DET
cana-5045	26	23	male	male	ADJ
cana-5045	26	24	fertility	fertility	NOUN
cana-5045	26	25	and	and	CCONJ
cana-5045	26	26	overall	overall	ADJ
cana-5045	26	27	reproduction	reproduction	NOUN
cana-5045	26	28	functions(røste	functions(røste	PROPN
cana-5045	26	29	et	et	NOUN
cana-5045	26	30	al	al	PROPN
cana-5045	26	31	.	.	PROPN
cana-5045	26	32	2005	2005	NUM
cana-5045	26	33	)	)	PUNCT
cana-5045	26	34	.	.	PUNCT
cana-5045	27	1	these	these	DET
cana-5045	27	2	findings	finding	NOUN
cana-5045	27	3	are	be	AUX
cana-5045	27	4	potentially	potentially	ADV
cana-5045	27	5	relevant	relevant	ADJ
cana-5045	27	6	,	,	PUNCT
cana-5045	27	7	given	give	VERB
cana-5045	27	8	the	the	DET
cana-5045	27	9	growing	grow	VERB
cana-5045	27	10	utilization	utilization	NOUN
cana-5045	27	11	of	of	ADP
cana-5045	27	12	valproate	valproate	NOUN
cana-5045	27	13	in	in	ADP
cana-5045	27	14	clinical	clinical	ADJ
cana-5045	27	15	practice	practice	NOUN
cana-5045	27	16	.	.	PUNCT
cana-5045	28	1	this	this	DET
cana-5045	28	2	study	study	NOUN
cana-5045	28	3	highlights	highlight	VERB
cana-5045	28	4	reproductive	reproductive	ADJ
cana-5045	28	5	risks	risk	NOUN
cana-5045	28	6	of	of	ADP
cana-5045	28	7	valproate	valproate	ADJ
cana-5045	28	8	therapy	therapy	NOUN
cana-5045	28	9	that	that	PRON
cana-5045	28	10	healthcare	healthcare	NOUN
cana-5045	28	11	providers	provider	NOUN
cana-5045	28	12	should	should	AUX
cana-5045	28	13	be	be	AUX
cana-5045	28	14	cognizant	cognizant	ADJ
cana-5045	28	15	and	and	CCONJ
cana-5045	28	16	vigilant	vigilant	ADJ
cana-5045	28	17	about	about	ADP
cana-5045	28	18	,	,	PUNCT
cana-5045	28	19	especially	especially	ADV
cana-5045	28	20	in	in	ADP
cana-5045	28	21	men	man	NOUN
cana-5045	28	22	in	in	ADP
cana-5045	28	23	their	their	PRON
cana-5045	28	24	childbearing	childbearing	NOUN
cana-5045	28	25	years	year	NOUN
cana-5045	28	26	.	.	PUNCT
cana-5045	29	1	this	this	DET
cana-5045	29	2	knowledge	knowledge	NOUN
cana-5045	29	3	is	be	AUX
cana-5045	29	4	critical	critical	ADJ
cana-5045	29	5	for	for	ADP
cana-5045	29	6	planning	plan	VERB
cana-5045	29	7	proper	proper	ADJ
cana-5045	29	8	management	management	NOUN
cana-5045	29	9	and	and	CCONJ
cana-5045	29	10	counseling	counseling	NOUN
cana-5045	29	11	of	of	ADP
cana-5045	29	12	patients	patient	NOUN
cana-5045	29	13	on	on	ADP
cana-5045	29	14	the	the	DET
cana-5045	29	15	potential	potential	ADJ
cana-5045	29	16	reproductive	reproductive	ADJ
cana-5045	29	17	health	health	NOUN
cana-5045	29	18	consequences	consequence	NOUN
cana-5045	29	19	of	of	ADP
cana-5045	29	20	treatment	treatment	NOUN
cana-5045	29	21	.	.	PUNCT
cana-5045	30	1	indeed	indeed	ADV
cana-5045	30	2	,	,	PUNCT
cana-5045	30	3	studies	study	NOUN
cana-5045	30	4	have	have	AUX
cana-5045	30	5	also	also	ADV
cana-5045	30	6	started	start	VERB
cana-5045	30	7	to	to	PART
cana-5045	30	8	investigate	investigate	VERB
cana-5045	30	9	possible	possible	ADJ
cana-5045	30	10	protective	protective	ADJ
cana-5045	30	11	strategies	strategy	NOUN
cana-5045	30	12	able	able	ADJ
cana-5045	30	13	to	to	PART
cana-5045	30	14	counteract	counteract	VERB
cana-5045	30	15	the	the	DET
cana-5045	30	16	adverse	adverse	ADJ
cana-5045	30	17	impact	impact	NOUN
cana-5045	30	18	of	of	ADP
cana-5045	30	19	valproate	valproate	NOUN
cana-5045	30	20	on	on	ADP
cana-5045	30	21	male	male	ADJ
cana-5045	30	22	fertility	fertility	NOUN
cana-5045	30	23	.	.	PUNCT
cana-5045	31	1	for	for	ADP
cana-5045	31	2	example	example	NOUN
cana-5045	31	3	,	,	PUNCT
cana-5045	31	4	treatment	treatment	NOUN
cana-5045	31	5	with	with	ADP
cana-5045	31	6	antioxidant	antioxidant	ADJ
cana-5045	31	7	supplementation	supplementation	NOUN
cana-5045	31	8	has	have	AUX
cana-5045	31	9	recently	recently	ADV
cana-5045	31	10	been	be	AUX
cana-5045	31	11	theorized	theorize	VERB
cana-5045	31	12	to	to	PART
cana-5045	31	13	alleviate	alleviate	VERB
cana-5045	31	14	oxidative	oxidative	ADJ
cana-5045	31	15	stress	stress	NOUN
cana-5045	31	16	and	and	CCONJ
cana-5045	31	17	enhance	enhance	VERB
cana-5045	31	18	reproductive	reproductive	ADJ
cana-5045	31	19	outcomes	outcome	NOUN
cana-5045	31	20	in	in	ADP
cana-5045	31	21	animal	animal	NOUN
cana-5045	31	22	models	model	NOUN
cana-5045	31	23	.	.	PUNCT
cana-5045	32	1	the	the	DET
cana-5045	32	2	aim	aim	NOUN
cana-5045	32	3	of	of	ADP
cana-5045	32	4	this	this	DET
cana-5045	32	5	review	review	NOUN
cana-5045	32	6	was	be	AUX
cana-5045	32	7	to	to	PART
cana-5045	32	8	assemble	assemble	VERB
cana-5045	32	9	a	a	DET
cana-5045	32	10	series	series	NOUN
cana-5045	32	11	of	of	ADP
cana-5045	32	12	studies	study	NOUN
cana-5045	32	13	focusing	focus	VERB
cana-5045	32	14	on	on	ADP
cana-5045	32	15	reproductive	reproductive	ADJ
cana-5045	32	16	outcomes	outcome	NOUN
cana-5045	32	17	in	in	ADP
cana-5045	32	18	men	man	NOUN
cana-5045	32	19	with	with	ADP
cana-5045	32	20	the	the	DET
cana-5045	32	21	overarching	overarching	ADJ
cana-5045	32	22	goal	goal	NOUN
cana-5045	32	23	that	that	PRON
cana-5045	32	24	they	they	PRON
cana-5045	32	25	provide	provide	VERB
cana-5045	32	26	an	an	DET
cana-5045	32	27	overall	overall	ADJ
cana-5045	32	28	perspective	perspective	NOUN
cana-5045	32	29	.	.	PUNCT
cana-5045	33	1	this	this	DET
cana-5045	33	2	paper	paper	NOUN
cana-5045	33	3	aims	aim	VERB
cana-5045	33	4	to	to	PART
cana-5045	33	5	review	review	VERB
cana-5045	33	6	literature	literature	NOUN
cana-5045	33	7	available	available	ADJ
cana-5045	33	8	on	on	ADP
cana-5045	33	9	the	the	DET
cana-5045	33	10	use	use	NOUN
cana-5045	33	11	of	of	ADP
cana-5045	33	12	valproate	valproate	NOUN
cana-5045	33	13	in	in	ADP
cana-5045	33	14	men	man	NOUN
cana-5045	33	15	with	with	ADP
cana-5045	33	16	epilepsy	epilepsy	NOUN
cana-5045	33	17	and	and	CCONJ
cana-5045	33	18	through	through	ADP
cana-5045	33	19	synthesizing	synthesize	VERB
cana-5045	33	20	research	research	NOUN
cana-5045	33	21	conducted	conduct	VERB
cana-5045	33	22	,	,	PUNCT
cana-5045	33	23	intends	intend	VERB
cana-5045	33	24	to	to	PART
cana-5045	33	25	emphasize	emphasize	VERB
cana-5045	33	26	both	both	DET
cana-5045	33	27	the	the	DET
cana-5045	33	28	need	need	NOUN
cana-5045	33	29	for	for	ADP
cana-5045	33	30	male	male	ADJ
cana-5045	33	31	reproductive	reproductive	ADJ
cana-5045	33	32	health	health	NOUN
cana-5045	33	33	considerations	consideration	NOUN
cana-5045	33	34	while	while	SCONJ
cana-5045	33	35	recommending	recommend	VERB
cana-5045	33	36	valproate	valproate	ADJ
cana-5045	33	37	as	as	ADV
cana-5045	33	38	well	well	ADV
cana-5045	33	39	as	as	ADP
cana-5045	33	40	suggest	suggest	VERB
cana-5045	33	41	areas	area	NOUN
cana-5045	33	42	for	for	ADP
cana-5045	33	43	further	further	ADJ
cana-5045	33	44	studies	study	NOUN
cana-5045	33	45	.	.	PUNCT
cana-5045	34	1	2	2	X
cana-5045	34	2	.	.	X
cana-5045	34	3	main	main	ADJ
cana-5045	34	4	body	body	NOUN
cana-5045	34	5	2.1	2.1	NUM
cana-5045	34	6	morphological	morphological	ADJ
cana-5045	34	7	and	and	CCONJ
cana-5045	34	8	functional	functional	ADJ
cana-5045	34	9	alterations	alteration	NOUN
cana-5045	34	10	in	in	ADP
cana-5045	34	11	the	the	DET
cana-5045	34	12	testis	testis	NOUN
cana-5045	34	13	diverse	diverse	ADJ
cana-5045	34	14	researches	research	NOUN
cana-5045	34	15	have	have	AUX
cana-5045	34	16	been	be	AUX
cana-5045	34	17	published	publish	VERB
cana-5045	34	18	using	use	VERB
cana-5045	34	19	animal	animal	NOUN
cana-5045	34	20	models	model	NOUN
cana-5045	34	21	to	to	PART
cana-5045	34	22	explore	explore	VERB
cana-5045	34	23	the	the	DET
cana-5045	34	24	morphological	morphological	ADJ
cana-5045	34	25	changes	change	NOUN
cana-5045	34	26	caused	cause	VERB
cana-5045	34	27	by	by	ADP
cana-5045	34	28	valproate(fereshetyan	valproate(fereshetyan	PROPN
cana-5045	34	29	et	et	PROPN
cana-5045	34	30	al	al	PROPN
cana-5045	34	31	.	.	PROPN
cana-5045	34	32	2021	2021	NUM
cana-5045	34	33	)	)	PUNCT
cana-5045	34	34	.	.	PUNCT
cana-5045	35	1	studies	study	NOUN
cana-5045	35	2	reported	report	VERB
cana-5045	35	3	that	that	SCONJ
cana-5045	35	4	long	long	ADJ
cana-5045	35	5	-	-	PUNCT
cana-5045	35	6	term	term	NOUN
cana-5045	35	7	treatment	treatment	NOUN
cana-5045	35	8	of	of	ADP
cana-5045	35	9	wistar	wistar	PROPN
cana-5045	35	10	rats	rat	NOUN
cana-5045	35	11	with	with	ADP
cana-5045	35	12	sodium	sodium	NOUN
cana-5045	35	13	valproate	valproate	ADJ
cana-5045	35	14	leads	lead	VERB
cana-5045	35	15	to	to	PART
cana-5045	35	16	cause	cause	VERB
cana-5045	35	17	marked	mark	VERB
cana-5045	35	18	testicular	testicular	ADJ
cana-5045	35	19	damage	damage	NOUN
cana-5045	35	20	.	.	PUNCT
cana-5045	36	1	degeneration	degeneration	NOUN
cana-5045	36	2	in	in	ADP
cana-5045	36	3	the	the	DET
cana-5045	36	4	seminiferous	seminiferous	ADJ
cana-5045	36	5	tubules	tubule	NOUN
cana-5045	36	6	and	and	CCONJ
cana-5045	36	7	decrease	decrease	VERB
cana-5045	36	8	number	number	NOUN
cana-5045	36	9	of	of	ADP
cana-5045	36	10	sperm	sperm	NOUN
cana-5045	36	11	was	be	AUX
cana-5045	36	12	observed	observe	VERB
cana-5045	36	13	histologically(røste	histologically(røste	PROPN
cana-5045	36	14	et	et	PROPN
cana-5045	36	15	al	al	PROPN
cana-5045	36	16	.	.	PROPN
cana-5045	36	17	2001	2001	NUM
cana-5045	36	18	)	)	PUNCT
cana-5045	36	19	.	.	PUNCT
cana-5045	37	1	these	these	DET
cana-5045	37	2	morphological	morphological	ADJ
cana-5045	37	3	changes	change	NOUN
cana-5045	37	4	are	be	AUX
cana-5045	37	5	in	in	ADP
cana-5045	37	6	agreement	agreement	NOUN
cana-5045	37	7	that	that	PRON
cana-5045	37	8	demonstrated	demonstrate	VERB
cana-5045	37	9	biochemical	biochemical	ADJ
cana-5045	37	10	changes	change	NOUN
cana-5045	37	11	in	in	ADP
cana-5045	37	12	reproductive	reproductive	ADJ
cana-5045	37	13	function	function	NOUN
cana-5045	37	14	parameters	parameter	NOUN
cana-5045	37	15	of	of	ADP
cana-5045	37	16	male	male	PROPN
cana-5045	37	17	wistar	wistar	PROPN
cana-5045	37	18	rats	rat	NOUN
cana-5045	37	19	subjected	subject	VERB
cana-5045	37	20	to	to	ADP
cana-5045	37	21	sodium	sodium	NOUN
cana-5045	37	22	valproate(vijay	valproate(vijay	NOUN
cana-5045	37	23	,	,	PUNCT
cana-5045	37	24	yeshwanth	yeshwanth	NOUN
cana-5045	37	25	,	,	PUNCT
cana-5045	37	26	and	and	CCONJ
cana-5045	37	27	bairy	bairy	NOUN
cana-5045	37	28	2008	2008	NUM
cana-5045	37	29	)	)	PUNCT
cana-5045	37	30	.	.	PUNCT
cana-5045	38	1	furthermore	furthermore	ADV
cana-5045	38	2	,	,	PUNCT
cana-5045	38	3	the	the	DET
cana-5045	38	4	semen	semen	NOUN
cana-5045	38	5	parameters	parameter	NOUN
cana-5045	38	6	as	as	ADV
cana-5045	38	7	well	well	ADV
cana-5045	38	8	showed	show	VERB
cana-5045	38	9	harmful	harmful	ADJ
cana-5045	38	10	effects	effect	NOUN
cana-5045	38	11	of	of	ADP
cana-5045	38	12	valproate	valproate	NOUN
cana-5045	38	13	on	on	ADP
cana-5045	38	14	sperm	sperm	NOUN
cana-5045	38	15	motility	motility	NOUN
cana-5045	38	16	and	and	CCONJ
cana-5045	38	17	morphology	morphology	NOUN
cana-5045	38	18	.	.	PUNCT
cana-5045	39	1	numerous	numerous	ADJ
cana-5045	39	2	studies	study	NOUN
cana-5045	39	3	showed	show	VERB
cana-5045	39	4	similar	similar	ADJ
cana-5045	39	5	findings	finding	NOUN
cana-5045	39	6	,	,	PUNCT
cana-5045	39	7	though	though	SCONJ
cana-5045	39	8	the	the	DET
cana-5045	39	9	affected	affect	VERB
cana-5045	39	10	fertile	fertile	ADJ
cana-5045	39	11	parameters	parameter	NOUN
cana-5045	39	12	were	be	AUX
cana-5045	39	13	only	only	ADV
cana-5045	39	14	sperm	sperm	NOUN
cana-5045	39	15	motility	motility	NOUN
cana-5045	39	16	and	and	CCONJ
cana-5045	39	17	testicular	testicular	ADJ
cana-5045	39	18	volume	volume	NOUN
cana-5045	39	19	;	;	PUNCT
cana-5045	39	20	with	with	ADP
cana-5045	39	21	men	man	NOUN
cana-5045	39	22	treated	treat	VERB
cana-5045	39	23	for	for	ADP
cana-5045	39	24	epilepsy	epilepsy	NOUN
cana-5045	39	25	using	use	VERB
cana-5045	39	26	valproate	valproate	ADJ
cana-5045	39	27	communications	communication	NOUN
cana-5045	39	28	on	on	ADP
cana-5045	39	29	applied	apply	VERB
cana-5045	39	30	nonlinear	nonlinear	ADJ
cana-5045	39	31	analysis	analysis	NOUN
cana-5045	39	32	issn	issn	NOUN
cana-5045	39	33	:	:	PUNCT
cana-5045	39	34	1074	1074	NUM
cana-5045	39	35	-	-	PUNCT
cana-5045	39	36	133x	133x	NUM
cana-5045	39	37	vol	vol	NOUN
cana-5045	39	38	32	32	NUM
cana-5045	39	39	no	no	NOUN
cana-5045	39	40	.	.	PUNCT
cana-5045	40	1	icmasd	icmasd	NOUN
cana-5045	40	2	(	(	PUNCT
cana-5045	40	3	2025	2025	NUM
cana-5045	40	4	)	)	PUNCT
cana-5045	40	5	176	176	NUM
cana-5045	40	6	https://internationalpubls.com	https://internationalpubls.com	X
cana-5045	40	7	demonstrating	demonstrate	VERB
cana-5045	40	8	lower	low	ADJ
cana-5045	40	9	levels	level	NOUN
cana-5045	40	10	of	of	ADP
cana-5045	40	11	these	these	DET
cana-5045	40	12	two	two	NUM
cana-5045	40	13	characteristics(hamed	characteristics(hame	VERB
cana-5045	40	14	et	et	PROPN
cana-5045	40	15	al	al	PROPN
cana-5045	40	16	.	.	PROPN
cana-5045	40	17	2015	2015	NUM
cana-5045	40	18	)	)	PUNCT
cana-5045	40	19	.	.	PUNCT
cana-5045	41	1	further	further	ADJ
cana-5045	41	2	investigations	investigation	NOUN
cana-5045	41	3	described	describe	VERB
cana-5045	41	4	changes	change	NOUN
cana-5045	41	5	in	in	ADP
cana-5045	41	6	sperm	sperm	NOUN
cana-5045	41	7	head	head	NOUN
cana-5045	41	8	morphology	morphology	NOUN
cana-5045	41	9	also	also	ADV
cana-5045	41	10	appear	appear	VERB
cana-5045	41	11	to	to	PART
cana-5045	41	12	be	be	AUX
cana-5045	41	13	directly	directly	ADV
cana-5045	41	14	related	relate	VERB
cana-5045	41	15	and	and	CCONJ
cana-5045	41	16	focused	focus	VERB
cana-5045	41	17	on	on	ADP
cana-5045	41	18	the	the	DET
cana-5045	41	19	permanent	permanent	ADJ
cana-5045	41	20	injury	injury	NOUN
cana-5045	41	21	of	of	ADP
cana-5045	41	22	germ	germ	NOUN
cana-5045	41	23	cells	cell	NOUN
cana-5045	41	24	likely	likely	ADV
cana-5045	41	25	induced	induce	VERB
cana-5045	41	26	by	by	ADP
cana-5045	41	27	valproate(trivedi	valproate(trivedi	PROPN
cana-5045	41	28	et	et	PROPN
cana-5045	41	29	al	al	PROPN
cana-5045	41	30	.	.	PROPN
cana-5045	41	31	2010	2010	NUM
cana-5045	41	32	)	)	PUNCT
cana-5045	41	33	.	.	PUNCT
cana-5045	42	1	2.2	2.2	NUM
cana-5045	42	2	hormonal	hormonal	ADJ
cana-5045	42	3	imbalance	imbalance	NOUN
cana-5045	42	4	and	and	CCONJ
cana-5045	42	5	oxidative	oxidative	ADJ
cana-5045	42	6	stress	stress	NOUN
cana-5045	42	7	the	the	DET
cana-5045	42	8	effects	effect	NOUN
cana-5045	42	9	of	of	ADP
cana-5045	42	10	sodium	sodium	NOUN
cana-5045	42	11	valproate	valproate	ADJ
cana-5045	42	12	on	on	ADP
cana-5045	42	13	male	male	ADJ
cana-5045	42	14	reproductive	reproductive	ADJ
cana-5045	42	15	health	health	NOUN
cana-5045	42	16	are	be	AUX
cana-5045	42	17	not	not	PART
cana-5045	42	18	only	only	ADV
cana-5045	42	19	due	due	ADJ
cana-5045	42	20	to	to	ADP
cana-5045	42	21	the	the	DET
cana-5045	42	22	structural	structural	ADJ
cana-5045	42	23	changes	change	NOUN
cana-5045	42	24	,	,	PUNCT
cana-5045	42	25	but	but	CCONJ
cana-5045	42	26	also	also	ADV
cana-5045	42	27	brought	bring	VERB
cana-5045	42	28	about	about	ADP
cana-5045	42	29	by	by	ADP
cana-5045	42	30	hormonal	hormonal	ADJ
cana-5045	42	31	disturbance(harden	disturbance(harden	PROPN
cana-5045	42	32	and	and	CCONJ
cana-5045	42	33	pennell	pennell	PROPN
cana-5045	42	34	2013	2013	NUM
cana-5045	42	35	)	)	PUNCT
cana-5045	42	36	.	.	PUNCT
cana-5045	43	1	various	various	ADJ
cana-5045	43	2	examinations	examination	NOUN
cana-5045	43	3	authenticated	authenticate	VERB
cana-5045	43	4	that	that	SCONJ
cana-5045	43	5	testosterone	testosterone	NOUN
cana-5045	43	6	levels	level	NOUN
cana-5045	43	7	were	be	AUX
cana-5045	43	8	measured	measure	VERB
cana-5045	43	9	in	in	ADP
cana-5045	43	10	men	man	NOUN
cana-5045	43	11	treated	treat	VERB
cana-5045	43	12	with	with	ADP
cana-5045	43	13	valproate	valproate	ADJ
cana-5045	43	14	and	and	CCONJ
cana-5045	43	15	hormone	hormone	NOUN
cana-5045	43	16	concentrations	concentration	NOUN
cana-5045	43	17	that	that	PRON
cana-5045	43	18	had	have	VERB
cana-5045	43	19	no	no	DET
cana-5045	43	20	impact	impact	NOUN
cana-5045	43	21	on	on	ADP
cana-5045	43	22	male	male	ADJ
cana-5045	43	23	reproductive	reproductive	NOUN
cana-5045	43	24	potential(chen	potential(chen	PROPN
cana-5045	43	25	et	et	PROPN
cana-5045	43	26	al	al	PROPN
cana-5045	43	27	.	.	PROPN
cana-5045	43	28	1992	1992	NUM
cana-5045	43	29	)	)	PUNCT
cana-5045	43	30	.	.	PUNCT
cana-5045	44	1	this	this	DET
cana-5045	44	2	hormonal	hormonal	ADJ
cana-5045	44	3	imbalance	imbalance	NOUN
cana-5045	44	4	could	could	AUX
cana-5045	44	5	lead	lead	VERB
cana-5045	44	6	to	to	ADP
cana-5045	44	7	the	the	DET
cana-5045	44	8	reproductive	reproductive	ADJ
cana-5045	44	9	disturbance	disturbance	NOUN
cana-5045	44	10	.	.	PUNCT
cana-5045	45	1	these	these	DET
cana-5045	45	2	antiepileptic	antiepileptic	ADJ
cana-5045	45	3	drugs	drug	NOUN
cana-5045	45	4	can	can	AUX
cana-5045	45	5	affect	affect	VERB
cana-5045	45	6	male	male	ADJ
cana-5045	45	7	reproductive	reproductive	ADJ
cana-5045	45	8	health	health	NOUN
cana-5045	45	9	markedly(isojärvi	markedly(isojärvi	PROPN
cana-5045	45	10	et	et	PROPN
cana-5045	45	11	al	al	PROPN
cana-5045	45	12	.	.	PROPN
cana-5045	45	13	2004	2004	NUM
cana-5045	45	14	)	)	PUNCT
cana-5045	45	15	.	.	PUNCT
cana-5045	46	1	valproate	valproate	PROPN
cana-5045	46	2	's	's	PART
cana-5045	46	3	adverse	adverse	ADJ
cana-5045	46	4	effects	effect	NOUN
cana-5045	46	5	are	be	AUX
cana-5045	46	6	mediated	mediate	VERB
cana-5045	46	7	through	through	ADP
cana-5045	46	8	oxidative	oxidative	ADJ
cana-5045	46	9	stress	stress	NOUN
cana-5045	46	10	.	.	PUNCT
cana-5045	47	1	a	a	DET
cana-5045	47	2	research	research	NOUN
cana-5045	47	3	demonstrated	demonstrate	VERB
cana-5045	47	4	the	the	DET
cana-5045	47	5	oxidative	oxidative	ADJ
cana-5045	47	6	harm	harm	NOUN
cana-5045	47	7	to	to	ADP
cana-5045	47	8	germ	germ	NOUN
cana-5045	47	9	cells	cell	NOUN
cana-5045	47	10	triggered	trigger	VERB
cana-5045	47	11	by	by	ADP
cana-5045	47	12	sodium	sodium	NOUN
cana-5045	47	13	valproate	valproate	NOUN
cana-5045	47	14	,	,	PUNCT
cana-5045	47	15	indicating	indicate	VERB
cana-5045	47	16	that	that	SCONJ
cana-5045	47	17	this	this	DET
cana-5045	47	18	resulting	result	VERB
cana-5045	47	19	stress	stress	NOUN
cana-5045	47	20	is	be	AUX
cana-5045	47	21	an	an	DET
cana-5045	47	22	important	important	ADJ
cana-5045	47	23	factor	factor	NOUN
cana-5045	47	24	in	in	ADP
cana-5045	47	25	genotoxicity	genotoxicity	NOUN
cana-5045	47	26	and	and	CCONJ
cana-5045	47	27	reduced	reduce	VERB
cana-5045	47	28	reproductive	reproductive	ADJ
cana-5045	47	29	ability(safdar	ability(safdar	PROPN
cana-5045	47	30	and	and	CCONJ
cana-5045	47	31	ismail	ismail	NOUN
cana-5045	47	32	2023	2023	NUM
cana-5045	47	33	)	)	PUNCT
cana-5045	47	34	.	.	PUNCT
cana-5045	48	1	there	there	PRON
cana-5045	48	2	is	be	VERB
cana-5045	48	3	growing	grow	VERB
cana-5045	48	4	evidences	evidence	NOUN
cana-5045	48	5	that	that	SCONJ
cana-5045	48	6	vitamin	vitamin	NOUN
cana-5045	48	7	e	e	NOUN
cana-5045	48	8	supplementation	supplementation	NOUN
cana-5045	48	9	might	might	AUX
cana-5045	48	10	be	be	AUX
cana-5045	48	11	beneficial	beneficial	ADJ
cana-5045	48	12	as	as	ADP
cana-5045	48	13	an	an	DET
cana-5045	48	14	initial	initial	ADJ
cana-5045	48	15	protective	protective	ADJ
cana-5045	48	16	strategy	strategy	NOUN
cana-5045	48	17	in	in	ADP
cana-5045	48	18	the	the	DET
cana-5045	48	19	prevention	prevention	NOUN
cana-5045	48	20	of	of	ADP
cana-5045	48	21	valproate	valproate	NOUN
cana-5045	48	22	-	-	PUNCT
cana-5045	48	23	induced	induce	VERB
cana-5045	48	24	testicular	testicular	ADJ
cana-5045	48	25	injury	injury	NOUN
cana-5045	48	26	,	,	PUNCT
cana-5045	48	27	and	and	CCONJ
cana-5045	48	28	shown	show	VERB
cana-5045	48	29	a	a	DET
cana-5045	48	30	significant	significant	ADJ
cana-5045	48	31	decrease	decrease	NOUN
cana-5045	48	32	in	in	ADP
cana-5045	48	33	tac	tac	PROPN
cana-5045	48	34	levels	level	NOUN
cana-5045	48	35	;	;	PUNCT
cana-5045	48	36	however	however	SCONJ
cana-5045	48	37	author	author	NOUN
cana-5045	48	38	detected	detect	VERB
cana-5045	48	39	adequate	adequate	ADJ
cana-5045	48	40	plasma	plasma	NOUN
cana-5045	48	41	glutathione	glutathione	NOUN
cana-5045	48	42	(	(	PUNCT
cana-5045	48	43	gsh	gsh	PROPN
cana-5045	48	44	)	)	PUNCT
cana-5045	48	45	values	value	NOUN
cana-5045	48	46	which	which	PRON
cana-5045	48	47	were	be	AUX
cana-5045	48	48	probably	probably	ADV
cana-5045	48	49	stoichiometrically	stoichiometrically	ADV
cana-5045	48	50	oxidized	oxidize	VERB
cana-5045	48	51	at	at	ADP
cana-5045	48	52	about	about	ADV
cana-5045	48	53	90	90	NUM
cana-5045	48	54	%	%	NOUN
cana-5045	48	55	due	due	ADP
cana-5045	48	56	to	to	ADP
cana-5045	48	57	vpa	vpa	PROPN
cana-5045	48	58	treatment	treatment	NOUN
cana-5045	48	59	since	since	SCONJ
cana-5045	48	60	urine	urine	NOUN
cana-5045	48	61	malondialdehyde	malondialdehyde	NOUN
cana-5045	48	62	(	(	PUNCT
cana-5045	48	63	mda	mda	PROPN
cana-5045	48	64	)	)	PUNCT
cana-5045	48	65	values	value	NOUN
cana-5045	48	66	increased	increase	VERB
cana-5045	48	67	nearly	nearly	ADV
cana-5045	48	68	fourfold	fourfold	ADV
cana-5045	48	69	compared	compare	VERB
cana-5045	48	70	with	with	ADP
cana-5045	48	71	control	control	NOUN
cana-5045	48	72	group	group	NOUN
cana-5045	48	73	fortifying	fortify	VERB
cana-5045	48	74	poor	poor	ADJ
cana-5045	48	75	efficiency	efficiency	NOUN
cana-5045	48	76	against	against	ADP
cana-5045	48	77	peroxidative	peroxidative	ADJ
cana-5045	48	78	stress	stress	NOUN
cana-5045	48	79	though	though	SCONJ
cana-5045	48	80	good	good	ADJ
cana-5045	48	81	capacity	capacity	NOUN
cana-5045	48	82	present	present	ADJ
cana-5045	48	83	for	for	ADP
cana-5045	48	84	defense	defense	NOUN
cana-5045	48	85	biochemical	biochemical	ADJ
cana-5045	48	86	pathways	pathway	NOUN
cana-5045	48	87	yet	yet	ADV
cana-5045	48	88	not	not	PART
cana-5045	48	89	activated	activate	VERB
cana-5045	48	90	fully	fully	ADV
cana-5045	48	91	as	as	SCONJ
cana-5045	48	92	it	it	PRON
cana-5045	48	93	seem	seem	VERB
cana-5045	48	94	from	from	ADP
cana-5045	48	95	enzyme	enzyme	NOUN
cana-5045	48	96	antioxidant	antioxidant	ADJ
cana-5045	48	97	activity	activity	NOUN
cana-5045	48	98	results(alsemeh	results(alsemeh	NOUN
cana-5045	48	99	et	et	PROPN
cana-5045	48	100	al	al	PROPN
cana-5045	48	101	.	.	PROPN
cana-5045	48	102	2022	2022	NUM
cana-5045	48	103	)	)	PUNCT
cana-5045	48	104	.	.	PUNCT
cana-5045	49	1	3	3	X
cana-5045	49	2	.	.	X
cana-5045	49	3	summary	summary	NOUN
cana-5045	49	4	in	in	ADP
cana-5045	49	5	conclusion	conclusion	NOUN
cana-5045	49	6	,	,	PUNCT
cana-5045	49	7	the	the	DET
cana-5045	49	8	information	information	NOUN
cana-5045	49	9	provided	provide	VERB
cana-5045	49	10	from	from	ADP
cana-5045	49	11	this	this	DET
cana-5045	49	12	review	review	NOUN
cana-5045	49	13	clearly	clearly	ADV
cana-5045	49	14	demonstrates	demonstrate	VERB
cana-5045	49	15	the	the	DET
cana-5045	49	16	significant	significant	ADJ
cana-5045	49	17	harmful	harmful	ADJ
cana-5045	49	18	effects	effect	NOUN
cana-5045	49	19	of	of	ADP
cana-5045	49	20	valproic	valproic	ADJ
cana-5045	49	21	acid	acid	NOUN
cana-5045	49	22	at	at	ADP
cana-5045	49	23	the	the	DET
cana-5045	49	24	male	male	ADJ
cana-5045	49	25	reproductive	reproductive	ADJ
cana-5045	49	26	health	health	NOUN
cana-5045	49	27	.	.	PUNCT
cana-5045	50	1	this	this	PRON
cana-5045	50	2	emphasizes	emphasize	VERB
cana-5045	50	3	the	the	DET
cana-5045	50	4	complexity	complexity	NOUN
cana-5045	50	5	between	between	ADP
cana-5045	50	6	pharmacological	pharmacological	NOUN
cana-5045	50	7	-	-	PUNCT
cana-5045	50	8	reproductive	reproductive	NOUN
cana-5045	50	9	parameter	parameter	NOUN
cana-5045	50	10	interplay	interplay	NOUN
cana-5045	50	11	,	,	PUNCT
cana-5045	50	12	reviewing	review	VERB
cana-5045	50	13	morphological	morphological	ADJ
cana-5045	50	14	testis	testis	NOUN
cana-5045	50	15	changes	change	NOUN
cana-5045	50	16	;	;	PUNCT
cana-5045	50	17	hormonal	hormonal	ADJ
cana-5045	50	18	imbalance	imbalance	NOUN
cana-5045	50	19	and	and	CCONJ
cana-5045	50	20	oxidative	oxidative	ADJ
cana-5045	50	21	stress	stress	NOUN
cana-5045	50	22	,	,	PUNCT
cana-5045	50	23	which	which	PRON
cana-5045	50	24	provide	provide	VERB
cana-5045	50	25	further	further	ADJ
cana-5045	50	26	insights	insight	NOUN
cana-5045	50	27	.	.	PUNCT
cana-5045	51	1	epidemiological	epidemiological	ADJ
cana-5045	51	2	studies	study	NOUN
cana-5045	51	3	have	have	AUX
cana-5045	51	4	indicated	indicate	VERB
cana-5045	51	5	that	that	SCONJ
cana-5045	51	6	the	the	DET
cana-5045	51	7	use	use	NOUN
cana-5045	51	8	of	of	ADP
cana-5045	51	9	valproic	valproic	ADJ
cana-5045	51	10	acid	acid	NOUN
cana-5045	51	11	is	be	AUX
cana-5045	51	12	high	high	ADJ
cana-5045	51	13	for	for	ADP
cana-5045	51	14	clinical	clinical	ADJ
cana-5045	51	15	epilepsy	epilepsy	NOUN
cana-5045	51	16	,	,	PUNCT
cana-5045	51	17	and	and	CCONJ
cana-5045	51	18	hence	hence	ADV
cana-5045	51	19	health	health	NOUN
cana-5045	51	20	care	care	NOUN
cana-5045	51	21	practitioners	practitioner	NOUN
cana-5045	51	22	should	should	AUX
cana-5045	51	23	be	be	AUX
cana-5045	51	24	made	make	VERB
cana-5045	51	25	aware	aware	ADJ
cana-5045	51	26	about	about	ADP
cana-5045	51	27	these	these	DET
cana-5045	51	28	potential	potential	ADJ
cana-5045	51	29	risks	risk	NOUN
cana-5045	51	30	while	while	SCONJ
cana-5045	51	31	they	they	PRON
cana-5045	51	32	consult	consult	VERB
cana-5045	51	33	their	their	PRON
cana-5045	51	34	male	male	ADJ
cana-5045	51	35	patients	patient	NOUN
cana-5045	51	36	providing	provide	VERB
cana-5045	51	37	them	they	PRON
cana-5045	51	38	with	with	ADP
cana-5045	51	39	other	other	ADJ
cana-5045	51	40	options	option	NOUN
cana-5045	51	41	or	or	CCONJ
cana-5045	51	42	minimal	minimal	ADJ
cana-5045	51	43	strategies	strategy	NOUN
cana-5045	51	44	to	to	PART
cana-5045	51	45	protect	protect	VERB
cana-5045	51	46	from	from	ADP
cana-5045	51	47	this	this	DET
cana-5045	51	48	harm	harm	NOUN
cana-5045	51	49	.	.	PUNCT
cana-5045	52	1	additional	additional	ADJ
cana-5045	52	2	studies	study	NOUN
cana-5045	52	3	are	be	AUX
cana-5045	52	4	needed	need	VERB
cana-5045	52	5	to	to	PART
cana-5045	52	6	elucidate	elucidate	VERB
cana-5045	52	7	mechanisms	mechanism	NOUN
cana-5045	52	8	and	and	CCONJ
cana-5045	52	9	characterize	characterize	VERB
cana-5045	52	10	best	good	ADJ
cana-5045	52	11	clinical	clinical	ADJ
cana-5045	52	12	practice	practice	NOUN
cana-5045	52	13	for	for	ADP
cana-5045	52	14	monitoring	monitor	VERB
cana-5045	52	15	reproductive	reproductive	ADJ
cana-5045	52	16	health	health	NOUN
cana-5045	52	17	in	in	ADP
cana-5045	52	18	men	man	NOUN
cana-5045	52	19	on	on	ADP
cana-5045	52	20	valproate	valproate	ADJ
cana-5045	52	21	therapy	therapy	NOUN
cana-5045	52	22	.	.	PUNCT
cana-5045	53	1	acknowledgements	acknowledgement	NOUN
cana-5045	53	2	i	i	PRON
cana-5045	53	3	am	be	AUX
cana-5045	53	4	deeply	deeply	ADV
cana-5045	53	5	grateful	grateful	ADJ
cana-5045	53	6	to	to	ADP
cana-5045	53	7	all	all	DET
cana-5045	53	8	the	the	DET
cana-5045	53	9	participants	participant	NOUN
cana-5045	53	10	who	who	PRON
cana-5045	53	11	generously	generously	ADV
cana-5045	53	12	shared	share	VERB
cana-5045	53	13	their	their	PRON
cana-5045	53	14	time	time	NOUN
cana-5045	53	15	and	and	CCONJ
cana-5045	53	16	experiences	experience	NOUN
cana-5045	53	17	for	for	ADP
cana-5045	53	18	this	this	DET
cana-5045	53	19	research	research	NOUN
cana-5045	53	20	.	.	PUNCT
cana-5045	54	1	their	their	PRON
cana-5045	54	2	contributions	contribution	NOUN
cana-5045	54	3	have	have	AUX
cana-5045	54	4	been	be	AUX
cana-5045	54	5	instrumental	instrumental	ADJ
cana-5045	54	6	in	in	ADP
cana-5045	54	7	the	the	DET
cana-5045	54	8	success	success	NOUN
cana-5045	54	9	of	of	ADP
cana-5045	54	10	this	this	DET
cana-5045	54	11	study	study	NOUN
cana-5045	54	12	.	.	PUNCT
cana-5045	55	1	conflict	conflict	NOUN
cana-5045	55	2	of	of	ADP
cana-5045	55	3	interest	interest	NOUN
cana-5045	55	4	the	the	DET
cana-5045	55	5	authors	author	NOUN
cana-5045	55	6	declare	declare	VERB
cana-5045	55	7	that	that	SCONJ
cana-5045	55	8	there	there	PRON
cana-5045	55	9	is	be	VERB
cana-5045	55	10	no	no	DET
cana-5045	55	11	conflict	conflict	NOUN
cana-5045	55	12	of	of	ADP
cana-5045	55	13	interest	interest	NOUN
cana-5045	55	14	regarding	regard	VERB
cana-5045	55	15	the	the	DET
cana-5045	55	16	publication	publication	NOUN
cana-5045	55	17	of	of	ADP
cana-5045	55	18	this	this	DET
cana-5045	55	19	paper	paper	NOUN
cana-5045	55	20	.	.	PUNCT
cana-5045	56	1	communications	communication	NOUN
cana-5045	56	2	on	on	ADP
cana-5045	56	3	applied	apply	VERB
cana-5045	56	4	nonlinear	nonlinear	ADJ
cana-5045	56	5	analysis	analysis	NOUN
cana-5045	56	6	issn	issn	NOUN
cana-5045	56	7	:	:	PUNCT
cana-5045	56	8	1074	1074	NUM
cana-5045	56	9	-	-	PUNCT
cana-5045	56	10	133x	133x	NUM
cana-5045	56	11	vol	vol	NOUN
cana-5045	56	12	32	32	NUM
cana-5045	56	13	no	no	NOUN
cana-5045	56	14	.	.	PUNCT
cana-5045	57	1	icmasd	icmasd	NOUN
cana-5045	57	2	(	(	PUNCT
cana-5045	57	3	2025	2025	NUM
cana-5045	57	4	)	)	PUNCT
cana-5045	57	5	177	177	NUM
cana-5045	57	6	https://internationalpubls.com	https://internationalpubls.com	X
cana-5045	57	7	references	reference	NOUN
cana-5045	57	8	[	[	X
cana-5045	57	9	1	1	NUM
cana-5045	57	10	]	]	PUNCT
cana-5045	57	11	alsemeh	alsemeh	NOUN
cana-5045	57	12	,	,	PUNCT
cana-5045	57	13	amira	amira	PROPN
cana-5045	57	14	ebrahim	ebrahim	PROPN
cana-5045	57	15	,	,	PUNCT
cana-5045	57	16	marwa	marwa	PROPN
cana-5045	57	17	mahmood	mahmood	PROPN
cana-5045	57	18	ahmed	ahmed	PROPN
cana-5045	57	19	,	,	PUNCT
cana-5045	57	20	amal	amal	PROPN
cana-5045	57	21	fawzy	fawzy	PROPN
cana-5045	57	22	,	,	PUNCT
cana-5045	57	23	walaa	walaa	PROPN
cana-5045	57	24	samy	samy	PROPN
cana-5045	57	25	,	,	PUNCT
cana-5045	57	26	marwa	marwa	PROPN
cana-5045	57	27	tharwat	tharwat	VERB
cana-5045	57	28	,	,	PUNCT
cana-5045	57	29	and	and	CCONJ
cana-5045	57	30	samar	samar	PROPN
cana-5045	57	31	rezq	rezq	PROPN
cana-5045	57	32	.	.	PUNCT
cana-5045	58	1	2022	2022	NUM
cana-5045	58	2	.	.	PUNCT
cana-5045	59	1	‘	'	PUNCT
cana-5045	59	2	vitamin	vitamin	NOUN
cana-5045	59	3	e	e	NOUN
cana-5045	59	4	rescues	rescue	VERB
cana-5045	59	5	valproic	valproic	ADJ
cana-5045	59	6	acid	acid	NOUN
cana-5045	59	7	-	-	PUNCT
cana-5045	59	8	induced	induce	VERB
cana-5045	59	9	testicular	testicular	ADJ
cana-5045	59	10	injury	injury	NOUN
cana-5045	59	11	in	in	ADP
cana-5045	59	12	rats	rat	NOUN
cana-5045	59	13	:	:	PUNCT
cana-5045	59	14	role	role	NOUN
cana-5045	59	15	of	of	ADP
cana-5045	59	16	autophagy	autophagy	NOUN
cana-5045	59	17	’	'	PUNCT
cana-5045	59	18	.	.	PUNCT
cana-5045	60	1	life	life	NOUN
cana-5045	60	2	sciences	sciences	PROPN
cana-5045	60	3	296:120434	296:120434	PROPN
cana-5045	60	4	.	.	PUNCT
cana-5045	61	1	doi	doi	NOUN
cana-5045	61	2	:	:	PUNCT
cana-5045	61	3	10.1016	10.1016	NUM
cana-5045	61	4	/	/	SYM
cana-5045	61	5	j.lfs.2022.120434	j.lfs.2022.120434	PROPN
cana-5045	61	6	.	.	PUNCT
cana-5045	62	1	[	[	X
cana-5045	62	2	2	2	NUM
cana-5045	62	3	]	]	X
cana-5045	62	4	chen	chen	PROPN
cana-5045	62	5	,	,	PUNCT
cana-5045	62	6	shun‐sheng	shun‐sheng	PROPN
cana-5045	62	7	,	,	PUNCT
cana-5045	62	8	meng‐ru	meng‐ru	PROPN
cana-5045	62	9	shen	shen	NOUN
cana-5045	62	10	,	,	PUNCT
cana-5045	62	11	tsan‐ju	tsan‐ju	X
cana-5045	62	12	chen	chen	PROPN
cana-5045	62	13	,	,	PUNCT
cana-5045	62	14	and	and	CCONJ
cana-5045	62	15	shung‐long	shung‐long	PROPN
cana-5045	62	16	lai	lai	PROPN
cana-5045	62	17	.	.	PUNCT
cana-5045	62	18	1992	1992	NUM
cana-5045	62	19	.	.	PUNCT
cana-5045	63	1	‘	'	PUNCT
cana-5045	63	2	effects	effect	NOUN
cana-5045	63	3	of	of	ADP
cana-5045	63	4	antiepileptic	antiepileptic	ADJ
cana-5045	63	5	drugs	drug	NOUN
cana-5045	63	6	on	on	ADP
cana-5045	63	7	sperm	sperm	NOUN
cana-5045	63	8	motility	motility	NOUN
cana-5045	63	9	of	of	ADP
cana-5045	63	10	normal	normal	ADJ
cana-5045	63	11	controls	control	NOUN
cana-5045	63	12	and	and	CCONJ
cana-5045	63	13	epileptic	epileptic	ADJ
cana-5045	63	14	patients	patient	NOUN
cana-5045	63	15	with	with	ADP
cana-5045	63	16	long‐term	long‐term	NOUN
cana-5045	63	17	therapy	therapy	NOUN
cana-5045	63	18	’	'	PUNCT
cana-5045	63	19	.	.	PUNCT
cana-5045	64	1	epilepsia	epilepsia	PROPN
cana-5045	64	2	33(1):149–53	33(1):149–53	NUM
cana-5045	64	3	.	.	PUNCT
cana-5045	65	1	doi	doi	NOUN
cana-5045	65	2	:	:	PUNCT
cana-5045	65	3	10.1111	10.1111	NUM
cana-5045	65	4	/	/	SYM
cana-5045	65	5	j.1528	j.1528	X
cana-5045	65	6	-	-	PUNCT
cana-5045	65	7	1157.1992.tb02298.x	1157.1992.tb02298.x	NUM
cana-5045	65	8	.	.	PUNCT
cana-5045	66	1	[	[	X
cana-5045	66	2	3	3	NUM
cana-5045	66	3	]	]	PUNCT
cana-5045	66	4	fereshetyan	fereshetyan	NOUN
cana-5045	66	5	,	,	PUNCT
cana-5045	66	6	katarine	katarine	PROPN
cana-5045	66	7	,	,	PUNCT
cana-5045	66	8	vergine	vergine	PROPN
cana-5045	66	9	chavushyan	chavushyan	PROPN
cana-5045	66	10	,	,	PUNCT
cana-5045	66	11	margarita	margarita	PROPN
cana-5045	66	12	danielyan	danielyan	PROPN
cana-5045	66	13	,	,	PUNCT
cana-5045	66	14	and	and	CCONJ
cana-5045	66	15	konstantin	konstantin	PROPN
cana-5045	66	16	yenkoyan	yenkoyan	PROPN
cana-5045	66	17	.	.	PUNCT
cana-5045	66	18	2021	2021	NUM
cana-5045	66	19	.	.	PUNCT
cana-5045	67	1	‘	'	PUNCT
cana-5045	67	2	assessment	assessment	NOUN
cana-5045	67	3	of	of	ADP
cana-5045	67	4	behavioral	behavioral	ADJ
cana-5045	67	5	,	,	PUNCT
cana-5045	67	6	morphological	morphological	ADJ
cana-5045	67	7	and	and	CCONJ
cana-5045	67	8	electrophysiological	electrophysiological	ADJ
cana-5045	67	9	changes	change	NOUN
cana-5045	67	10	in	in	ADP
cana-5045	67	11	prenatal	prenatal	ADJ
cana-5045	67	12	and	and	CCONJ
cana-5045	67	13	postnatal	postnatal	ADJ
cana-5045	67	14	valproate	valproate	ADJ
cana-5045	67	15	induced	induce	VERB
cana-5045	67	16	rat	rat	NOUN
cana-5045	67	17	models	model	NOUN
cana-5045	67	18	of	of	ADP
cana-5045	67	19	autism	autism	NOUN
cana-5045	67	20	spectrum	spectrum	NOUN
cana-5045	67	21	disorder	disorder	NOUN
cana-5045	67	22	’	'	PUNCT
cana-5045	67	23	.	.	PUNCT
cana-5045	68	1	scientific	scientific	ADJ
cana-5045	68	2	reports	report	NOUN
cana-5045	68	3	11(1):23471	11(1):23471	NUM
cana-5045	68	4	.	.	PUNCT
cana-5045	69	1	doi	doi	NOUN
cana-5045	69	2	:	:	PUNCT
cana-5045	69	3	10.1038	10.1038	NUM
cana-5045	69	4	/	/	SYM
cana-5045	69	5	s41598	s41598	NOUN
cana-5045	69	6	-	-	PUNCT
cana-5045	69	7	021	021	NUM
cana-5045	69	8	-	-	PUNCT
cana-5045	69	9	02994	02994	NUM
cana-5045	69	10	-	-	PUNCT
cana-5045	69	11	6	6	NUM
cana-5045	69	12	.	.	PUNCT
cana-5045	70	1	[	[	X
cana-5045	70	2	4	4	NUM
cana-5045	70	3	]	]	X
cana-5045	70	4	hamed	hamed	PROPN
cana-5045	70	5	,	,	PUNCT
cana-5045	70	6	sherifa	sherifa	PROPN
cana-5045	70	7	a.	a.	PROPN
cana-5045	70	8	,	,	PUNCT
cana-5045	70	9	ehab	ehab	PROPN
cana-5045	70	10	m.	m.	PROPN
cana-5045	70	11	m.	m.	PROPN
cana-5045	70	12	moussa	moussa	PROPN
cana-5045	70	13	,	,	PUNCT
cana-5045	70	14	amal	amal	PROPN
cana-5045	70	15	m.	m.	NOUN
cana-5045	70	16	tohamy	tohamy	NOUN
cana-5045	70	17	,	,	PUNCT
cana-5045	70	18	khaled	khaled	PROPN
cana-5045	70	19	o.	o.	PROPN
cana-5045	70	20	mohamed	mohamed	PROPN
cana-5045	70	21	,	,	PUNCT
cana-5045	70	22	mohamad	mohamad	PROPN
cana-5045	70	23	e.	e.	PROPN
cana-5045	70	24	mohamad	mohamad	PROPN
cana-5045	70	25	,	,	PUNCT
cana-5045	70	26	tahra	tahra	ADJ
cana-5045	70	27	m.	m.	PROPN
cana-5045	70	28	k.	k.	PROPN
cana-5045	70	29	sherif	sherif	PROPN
cana-5045	70	30	,	,	PUNCT
cana-5045	70	31	and	and	CCONJ
cana-5045	70	32	mostafa	mostafa	PROPN
cana-5045	70	33	m.	m.	PROPN
cana-5045	70	34	abdellah	abdellah	PROPN
cana-5045	70	35	.	.	PROPN
cana-5045	71	1	2015	2015	NUM
cana-5045	71	2	.	.	PUNCT
cana-5045	72	1	‘	'	PUNCT
cana-5045	72	2	seminal	seminal	ADJ
cana-5045	72	3	fluid	fluid	ADJ
cana-5045	72	4	analysis	analysis	NOUN
cana-5045	72	5	and	and	CCONJ
cana-5045	72	6	testicular	testicular	ADJ
cana-5045	72	7	volume	volume	NOUN
cana-5045	72	8	in	in	ADP
cana-5045	72	9	adults	adult	NOUN
cana-5045	72	10	with	with	ADP
cana-5045	72	11	epilepsy	epilepsy	NOUN
cana-5045	72	12	receiving	receive	VERB
cana-5045	72	13	valproate	valproate	NOUN
cana-5045	72	14	’	'	PUNCT
cana-5045	72	15	.	.	PUNCT
cana-5045	73	1	journal	journal	PROPN
cana-5045	73	2	of	of	ADP
cana-5045	73	3	clinical	clinical	ADJ
cana-5045	73	4	neuroscience	neuroscience	NOUN
cana-5045	73	5	22(3):508–12	22(3):508–12	PROPN
cana-5045	73	6	.	.	PUNCT
cana-5045	74	1	doi	doi	PROPN
cana-5045	74	2	:	:	PUNCT
cana-5045	74	3	10.1016	10.1016	NUM
cana-5045	74	4	/	/	SYM
cana-5045	74	5	j.jocn.2014.08.029	j.jocn.2014.08.029	PROPN
cana-5045	74	6	.	.	PUNCT
cana-5045	75	1	[	[	X
cana-5045	75	2	5	5	NUM
cana-5045	75	3	]	]	PUNCT
cana-5045	75	4	harden	harden	NOUN
cana-5045	75	5	,	,	PUNCT
cana-5045	75	6	cynthia	cynthia	PROPN
cana-5045	75	7	l.	l.	PROPN
cana-5045	75	8	,	,	PUNCT
cana-5045	75	9	and	and	CCONJ
cana-5045	75	10	page	page	PROPN
cana-5045	75	11	b.	b.	PROPN
cana-5045	75	12	pennell	pennell	PROPN
cana-5045	75	13	.	.	PUNCT
cana-5045	76	1	2013	2013	NUM
cana-5045	76	2	.	.	PUNCT
cana-5045	77	1	‘	'	PUNCT
cana-5045	77	2	neuroendocrine	neuroendocrine	ADJ
cana-5045	77	3	considerations	consideration	NOUN
cana-5045	77	4	in	in	ADP
cana-5045	77	5	the	the	DET
cana-5045	77	6	treatment	treatment	NOUN
cana-5045	77	7	of	of	ADP
cana-5045	77	8	men	man	NOUN
cana-5045	77	9	and	and	CCONJ
cana-5045	77	10	women	woman	NOUN
cana-5045	77	11	with	with	ADP
cana-5045	77	12	epilepsy	epilepsy	NOUN
cana-5045	77	13	’	'	PUNCT
cana-5045	77	14	.	.	PUNCT
cana-5045	78	1	the	the	DET
cana-5045	78	2	lancet	lancet	PROPN
cana-5045	78	3	neurology	neurology	NOUN
cana-5045	78	4	12(1):72–83	12(1):72–83	NUM
cana-5045	78	5	.	.	PUNCT
cana-5045	79	1	doi	doi	NOUN
cana-5045	79	2	:	:	PUNCT
cana-5045	79	3	10.1016	10.1016	NUM
cana-5045	79	4	/	/	SYM
cana-5045	79	5	s1474	s1474	PROPN
cana-5045	79	6	-	-	NOUN
cana-5045	79	7	4422(12)70239	4422(12)70239	NUM
cana-5045	79	8	-	-	PUNCT
cana-5045	79	9	9	9	NUM
cana-5045	79	10	.	.	PUNCT
cana-5045	80	1	[	[	X
cana-5045	80	2	6	6	NUM
cana-5045	80	3	]	]	PUNCT
cana-5045	80	4	iamsaard	iamsaard	NOUN
cana-5045	80	5	,	,	PUNCT
cana-5045	80	6	sitthichai	sitthichai	VERB
cana-5045	80	7	,	,	PUNCT
cana-5045	80	8	1.department	1.department	NUM
cana-5045	80	9	of	of	ADP
cana-5045	80	10	anatomy	anatomy	NOUN
cana-5045	80	11	,	,	PUNCT
cana-5045	80	12	faculty	faculty	NOUN
cana-5045	80	13	of	of	ADP
cana-5045	80	14	medicine	medicine	NOUN
cana-5045	80	15	,	,	PUNCT
cana-5045	80	16	khon	khon	PROPN
cana-5045	80	17	kaen	kaen	PROPN
cana-5045	80	18	university	university	PROPN
cana-5045	80	19	,	,	PUNCT
cana-5045	80	20	khon	khon	PROPN
cana-5045	80	21	kaen	kaen	PROPN
cana-5045	80	22	,	,	PUNCT
cana-5045	80	23	thailand	thailand	PROPN
cana-5045	80	24	.	.	PROPN
cana-5045	81	1	2.center	2.center	NUM
cana-5045	81	2	for	for	ADP
cana-5045	81	3	research	research	NOUN
cana-5045	81	4	and	and	CCONJ
cana-5045	81	5	development	development	NOUN
cana-5045	81	6	of	of	ADP
cana-5045	81	7	herbal	herbal	ADJ
cana-5045	81	8	health	health	NOUN
cana-5045	81	9	products	product	NOUN
cana-5045	81	10	,	,	PUNCT
cana-5045	81	11	faculty	faculty	NOUN
cana-5045	81	12	of	of	ADP
cana-5045	81	13	pharmaceutical	pharmaceutical	NOUN
cana-5045	81	14	sciences	science	NOUN
cana-5045	81	15	,	,	PUNCT
cana-5045	81	16	khon	khon	PROPN
cana-5045	81	17	kaen	kaen	PROPN
cana-5045	81	18	university	university	PROPN
cana-5045	81	19	,	,	PUNCT
cana-5045	81	20	khon	khon	PROPN
cana-5045	81	21	kaen	kaen	PROPN
cana-5045	81	22	40002	40002	NUM
cana-5045	81	23	,	,	PUNCT
cana-5045	81	24	thailand	thailand	PROPN
cana-5045	81	25	,	,	PUNCT
cana-5045	81	26	wannisa	wannisa	NOUN
cana-5045	81	27	sukhorum	sukhorum	NOUN
cana-5045	81	28	,	,	PUNCT
cana-5045	81	29	1.department	1.department	NUM
cana-5045	81	30	of	of	ADP
cana-5045	81	31	anatomy	anatomy	NOUN
cana-5045	81	32	,	,	PUNCT
cana-5045	81	33	faculty	faculty	NOUN
cana-5045	81	34	of	of	ADP
cana-5045	81	35	medicine	medicine	NOUN
cana-5045	81	36	,	,	PUNCT
cana-5045	81	37	khon	khon	PROPN
cana-5045	81	38	kaen	kaen	PROPN
cana-5045	81	39	university	university	PROPN
cana-5045	81	40	,	,	PUNCT
cana-5045	81	41	khon	khon	PROPN
cana-5045	81	42	kaen	kaen	PROPN
cana-5045	81	43	,	,	PUNCT
cana-5045	81	44	thailand.2.school	thailand.2.school	PROPN
cana-5045	81	45	of	of	ADP
cana-5045	81	46	medicine	medicine	NOUN
cana-5045	81	47	,	,	PUNCT
cana-5045	81	48	mae	mae	PROPN
cana-5045	81	49	fah	fah	PROPN
cana-5045	81	50	luang	luang	PROPN
cana-5045	81	51	university	university	PROPN
cana-5045	81	52	,	,	PUNCT
cana-5045	81	53	chiang	chiang	PROPN
cana-5045	81	54	rai	rai	PROPN
cana-5045	82	1	57100	57100	NUM
cana-5045	82	2	,	,	PUNCT
cana-5045	82	3	thailand	thailand	PROPN
cana-5045	82	4	.	.	PROPN
cana-5045	82	5	,	,	PUNCT
cana-5045	82	6	supatcharee	supatcharee	ADJ
cana-5045	82	7	arun	arun	PROPN
cana-5045	82	8	,	,	PUNCT
cana-5045	82	9	department	department	NOUN
cana-5045	82	10	of	of	ADP
cana-5045	82	11	anatomy	anatomy	NOUN
cana-5045	82	12	,	,	PUNCT
cana-5045	82	13	faculty	faculty	NOUN
cana-5045	82	14	of	of	ADP
cana-5045	82	15	medicine	medicine	NOUN
cana-5045	82	16	,	,	PUNCT
cana-5045	82	17	khon	khon	PROPN
cana-5045	82	18	kaen	kaen	PROPN
cana-5045	82	19	university	university	PROPN
cana-5045	82	20	,	,	PUNCT
cana-5045	82	21	khon	khon	PROPN
cana-5045	82	22	kaen	kaen	PROPN
cana-5045	82	23	,	,	PUNCT
cana-5045	82	24	thailand	thailand	PROPN
cana-5045	82	25	.	.	PROPN
cana-5045	82	26	,	,	PUNCT
cana-5045	82	27	nichapa	nichapa	VERB
cana-5045	82	28	phunchago	phunchago	PROPN
cana-5045	82	29	,	,	PUNCT
cana-5045	82	30	department	department	NOUN
cana-5045	82	31	of	of	ADP
cana-5045	82	32	anatomy	anatomy	NOUN
cana-5045	82	33	,	,	PUNCT
cana-5045	82	34	faculty	faculty	NOUN
cana-5045	82	35	of	of	ADP
cana-5045	82	36	medicine	medicine	NOUN
cana-5045	82	37	,	,	PUNCT
cana-5045	82	38	khon	khon	PROPN
cana-5045	82	39	kaen	kaen	PROPN
cana-5045	82	40	university	university	PROPN
cana-5045	82	41	,	,	PUNCT
cana-5045	82	42	khon	khon	PROPN
cana-5045	82	43	kaen	kaen	PROPN
cana-5045	82	44	,	,	PUNCT
cana-5045	82	45	thailand	thailand	PROPN
cana-5045	82	46	,	,	PUNCT
cana-5045	82	47	nongnuch	nongnuch	ADJ
cana-5045	82	48	uabundit	uabundit	NOUN
cana-5045	82	49	,	,	PUNCT
cana-5045	82	50	department	department	NOUN
cana-5045	82	51	of	of	ADP
cana-5045	82	52	anatomy	anatomy	NOUN
cana-5045	82	53	,	,	PUNCT
cana-5045	82	54	faculty	faculty	NOUN
cana-5045	82	55	of	of	ADP
cana-5045	82	56	medicine	medicine	NOUN
cana-5045	82	57	,	,	PUNCT
cana-5045	82	58	khon	khon	PROPN
cana-5045	82	59	kaen	kaen	PROPN
cana-5045	82	60	university	university	PROPN
cana-5045	82	61	,	,	PUNCT
cana-5045	82	62	khon	khon	PROPN
cana-5045	82	63	kaen	kaen	PROPN
cana-5045	82	64	,	,	PUNCT
cana-5045	82	65	thailand	thailand	PROPN
cana-5045	82	66	,	,	PUNCT
cana-5045	82	67	porntip	porntip	PROPN
cana-5045	82	68	boonruangsri	boonruangsri	PROPN
cana-5045	82	69	,	,	PUNCT
cana-5045	82	70	department	department	NOUN
cana-5045	82	71	of	of	ADP
cana-5045	82	72	anatomy	anatomy	NOUN
cana-5045	82	73	,	,	PUNCT
cana-5045	82	74	faculty	faculty	NOUN
cana-5045	82	75	of	of	ADP
cana-5045	82	76	medicine	medicine	NOUN
cana-5045	82	77	,	,	PUNCT
cana-5045	82	78	khon	khon	PROPN
cana-5045	82	79	kaen	kaen	PROPN
cana-5045	82	80	university	university	PROPN
cana-5045	82	81	,	,	PUNCT
cana-5045	82	82	khon	khon	PROPN
cana-5045	82	83	kaen	kaen	PROPN
cana-5045	82	84	,	,	PUNCT
cana-5045	82	85	thailand	thailand	PROPN
cana-5045	82	86	,	,	PUNCT
cana-5045	82	87	malivalaya	malivalaya	NOUN
cana-5045	82	88	namking	namking	NOUN
cana-5045	82	89	,	,	PUNCT
cana-5045	82	90	and	and	CCONJ
cana-5045	82	91	department	department	NOUN
cana-5045	82	92	of	of	ADP
cana-5045	82	93	anatomy	anatomy	NOUN
cana-5045	82	94	,	,	PUNCT
cana-5045	82	95	faculty	faculty	NOUN
cana-5045	82	96	of	of	ADP
cana-5045	82	97	medicine	medicine	NOUN
cana-5045	82	98	,	,	PUNCT
cana-5045	82	99	khon	khon	PROPN
cana-5045	82	100	kaen	kaen	PROPN
cana-5045	82	101	university	university	PROPN
cana-5045	82	102	,	,	PUNCT
cana-5045	82	103	khon	khon	PROPN
cana-5045	82	104	kaen	kaen	PROPN
cana-5045	82	105	,	,	PUNCT
cana-5045	82	106	thailand	thailand	PROPN
cana-5045	82	107	.	.	PROPN
cana-5045	82	108	2017	2017	NUM
cana-5045	82	109	.	.	PUNCT
cana-5045	83	1	‘	'	PUNCT
cana-5045	83	2	valproic	valproic	ADJ
cana-5045	83	3	acid	acid	NOUN
cana-5045	83	4	induces	induce	VERB
cana-5045	83	5	histologic	histologic	ADJ
cana-5045	83	6	changes	change	NOUN
cana-5045	83	7	and	and	CCONJ
cana-5045	83	8	decreases	decrease	VERB
cana-5045	83	9	androgen	androgen	NOUN
cana-5045	83	10	receptor	receptor	NOUN
cana-5045	83	11	levels	level	NOUN
cana-5045	83	12	of	of	ADP
cana-5045	83	13	testis	testis	NOUN
cana-5045	83	14	and	and	CCONJ
cana-5045	83	15	epididymis	epididymis	NOUN
cana-5045	83	16	in	in	ADP
cana-5045	83	17	rats	rat	NOUN
cana-5045	83	18	’	'	PUNCT
cana-5045	83	19	.	.	PUNCT
cana-5045	84	1	international	international	ADJ
cana-5045	84	2	journal	journal	PROPN
cana-5045	84	3	of	of	ADP
cana-5045	84	4	reproductive	reproductive	ADJ
cana-5045	84	5	biomedicine	biomedicine	NOUN
cana-5045	84	6	15(4):217–24	15(4):217–24	PROPN
cana-5045	84	7	.	.	PUNCT
cana-5045	85	1	doi	doi	NOUN
cana-5045	85	2	:	:	PUNCT
cana-5045	85	3	10.29252	10.29252	NUM
cana-5045	85	4	/	/	SYM
cana-5045	85	5	ijrm.15.4.217	ijrm.15.4.217	NUM
cana-5045	85	6	.	.	PUNCT
cana-5045	86	1	[	[	X
cana-5045	86	2	7	7	NUM
cana-5045	86	3	]	]	X
cana-5045	86	4	isojärvi	isojärvi	PROPN
cana-5045	86	5	,	,	PUNCT
cana-5045	86	6	j.	j.	PROPN
cana-5045	86	7	i.	i.	PROPN
cana-5045	86	8	t.	t.	PROPN
cana-5045	86	9	,	,	PUNCT
cana-5045	86	10	e.	e.	PROPN
cana-5045	86	11	löfgren	löfgren	PROPN
cana-5045	86	12	,	,	PUNCT
cana-5045	86	13	k.	k.	PROPN
cana-5045	86	14	s.	s.	PROPN
cana-5045	86	15	t.	t.	PROPN
cana-5045	86	16	juntunen	juntunen	PROPN
cana-5045	86	17	,	,	PUNCT
cana-5045	86	18	a.	a.	PROPN
cana-5045	86	19	j.	j.	PROPN
cana-5045	86	20	pakarinen	pakarinen	PROPN
cana-5045	86	21	,	,	PUNCT
cana-5045	86	22	m.	m.	NOUN
cana-5045	86	23	päivänsalo	päivänsalo	NOUN
cana-5045	86	24	,	,	PUNCT
cana-5045	86	25	i.	i.	PROPN
cana-5045	86	26	rautakorpi	rautakorpi	PROPN
cana-5045	86	27	,	,	PUNCT
cana-5045	86	28	and	and	CCONJ
cana-5045	86	29	l.	l.	PROPN
cana-5045	86	30	tuomivaara	tuomivaara	PROPN
cana-5045	86	31	.	.	PUNCT
cana-5045	87	1	2004	2004	NUM
cana-5045	87	2	.	.	PUNCT
cana-5045	88	1	‘	'	PUNCT
cana-5045	88	2	effect	effect	NOUN
cana-5045	88	3	of	of	ADP
cana-5045	88	4	epilepsy	epilepsy	NOUN
cana-5045	88	5	and	and	CCONJ
cana-5045	88	6	antiepileptic	antiepileptic	ADJ
cana-5045	88	7	drugs	drug	NOUN
cana-5045	88	8	on	on	ADP
cana-5045	88	9	male	male	ADJ
cana-5045	88	10	reproductive	reproductive	ADJ
cana-5045	88	11	health	health	NOUN
cana-5045	88	12	’	'	PUNCT
cana-5045	88	13	.	.	PUNCT
cana-5045	89	1	neurology	neurology	NOUN
cana-5045	89	2	62(2):247–53	62(2):247–53	PROPN
cana-5045	89	3	.	.	PUNCT
cana-5045	90	1	doi	doi	NOUN
cana-5045	90	2	:	:	PUNCT
cana-5045	90	3	10.1212/01.wnl.0000098936.46730.64	10.1212/01.wnl.0000098936.46730.64	NUM
cana-5045	90	4	.	.	PUNCT
cana-5045	91	1	[	[	X
cana-5045	91	2	8	8	NUM
cana-5045	91	3	]	]	X
cana-5045	91	4	khan	khan	PROPN
cana-5045	91	5	,	,	PUNCT
cana-5045	91	6	sabbir	sabbir	NOUN
cana-5045	91	7	,	,	PUNCT
cana-5045	91	8	tauseef	tauseef	ADJ
cana-5045	91	9	ahmad	ahmad	PROPN
cana-5045	91	10	,	,	PUNCT
cana-5045	91	11	chintan	chintan	PROPN
cana-5045	91	12	vishnubhai	vishnubhai	PROPN
cana-5045	91	13	parekh	parekh	PROPN
cana-5045	91	14	,	,	PUNCT
cana-5045	91	15	priyanka	priyanka	PROPN
cana-5045	91	16	pushkarbhai	pushkarbhai	PROPN
cana-5045	91	17	trivedi	trivedi	PROPN
cana-5045	91	18	,	,	PUNCT
cana-5045	91	19	sapana	sapana	PROPN
cana-5045	91	20	kushwaha	kushwaha	PROPN
cana-5045	91	21	,	,	PUNCT
cana-5045	91	22	and	and	CCONJ
cana-5045	91	23	gopabandhu	gopabandhu	PROPN
cana-5045	91	24	jena	jena	PROPN
cana-5045	91	25	.	.	PUNCT
cana-5045	92	1	2011	2011	NUM
cana-5045	92	2	.	.	PUNCT
cana-5045	93	1	‘	'	PUNCT
cana-5045	93	2	investigation	investigation	NOUN
cana-5045	93	3	on	on	ADP
cana-5045	93	4	sodium	sodium	NOUN
cana-5045	93	5	valproate	valproate	ADJ
cana-5045	93	6	induced	induce	VERB
cana-5045	93	7	germ	germ	NOUN
cana-5045	93	8	cell	cell	NOUN
cana-5045	93	9	damage	damage	NOUN
cana-5045	93	10	,	,	PUNCT
cana-5045	93	11	oxidative	oxidative	ADJ
cana-5045	93	12	stress	stress	NOUN
cana-5045	93	13	and	and	CCONJ
cana-5045	93	14	genotoxicity	genotoxicity	NOUN
cana-5045	93	15	in	in	ADP
cana-5045	93	16	male	male	ADJ
cana-5045	93	17	swiss	swiss	ADJ
cana-5045	93	18	mice	mouse	NOUN
cana-5045	93	19	’	'	PUNCT
cana-5045	93	20	.	.	PUNCT
cana-5045	94	1	reproductive	reproductive	ADJ
cana-5045	94	2	toxicology	toxicology	NOUN
cana-5045	94	3	32(4):385–94	32(4):385–94	NUM
cana-5045	94	4	.	.	PUNCT
cana-5045	95	1	doi	doi	NOUN
cana-5045	95	2	:	:	PUNCT
cana-5045	95	3	10.1016	10.1016	NUM
cana-5045	95	4	/	/	SYM
cana-5045	95	5	j.reprotox.2011.09.007	j.reprotox.2011.09.007	VERB
cana-5045	95	6	.	.	PUNCT
cana-5045	96	1	communications	communication	NOUN
cana-5045	96	2	on	on	ADP
cana-5045	96	3	applied	apply	VERB
cana-5045	96	4	nonlinear	nonlinear	ADJ
cana-5045	96	5	analysis	analysis	NOUN
cana-5045	96	6	issn	issn	NOUN
cana-5045	96	7	:	:	PUNCT
cana-5045	96	8	1074	1074	NUM
cana-5045	96	9	-	-	PUNCT
cana-5045	96	10	133x	133x	NUM
cana-5045	96	11	vol	vol	NOUN
cana-5045	96	12	32	32	NUM
cana-5045	96	13	no	no	NOUN
cana-5045	96	14	.	.	PUNCT
cana-5045	97	1	icmasd	icmasd	NOUN
cana-5045	97	2	(	(	PUNCT
cana-5045	97	3	2025	2025	NUM
cana-5045	97	4	)	)	PUNCT
cana-5045	97	5	178	178	NUM
cana-5045	97	6	https://internationalpubls.com	https://internationalpubls.com	X
cana-5045	98	1	[	[	X
cana-5045	98	2	9	9	NUM
cana-5045	98	3	]	]	X
cana-5045	98	4	mascarenhas	mascarenha	NOUN
cana-5045	98	5	,	,	PUNCT
cana-5045	98	6	caio	caio	PROPN
cana-5045	98	7	,	,	PUNCT
cana-5045	98	8	ana	ana	PROPN
cana-5045	98	9	c.	c.	PROPN
cana-5045	98	10	a.	a.	PROPN
cana-5045	98	11	sousa	sousa	PROPN
cana-5045	98	12	,	,	PUNCT
cana-5045	98	13	and	and	CCONJ
cana-5045	98	14	luís	luís	PROPN
cana-5045	98	15	rato	rato	PROPN
cana-5045	98	16	.	.	PROPN
cana-5045	98	17	2024	2024	NUM
cana-5045	98	18	.	.	PUNCT
cana-5045	99	1	‘	'	PUNCT
cana-5045	99	2	effects	effect	NOUN
cana-5045	99	3	of	of	ADP
cana-5045	99	4	pharmaceutical	pharmaceutical	ADJ
cana-5045	99	5	substances	substance	NOUN
cana-5045	99	6	with	with	ADP
cana-5045	99	7	obesogenic	obesogenic	ADJ
cana-5045	99	8	activity	activity	NOUN
cana-5045	99	9	on	on	ADP
cana-5045	99	10	male	male	ADJ
cana-5045	99	11	reproductive	reproductive	ADJ
cana-5045	99	12	health	health	NOUN
cana-5045	99	13	’	'	PUNCT
cana-5045	99	14	.	.	PUNCT
cana-5045	100	1	international	international	ADJ
cana-5045	100	2	journal	journal	NOUN
cana-5045	100	3	of	of	ADP
cana-5045	100	4	molecular	molecular	ADJ
cana-5045	100	5	sciences	science	NOUN
cana-5045	100	6	25(4):2324	25(4):2324	NUM
cana-5045	100	7	.	.	PUNCT
cana-5045	101	1	doi	doi	NOUN
cana-5045	101	2	:	:	PUNCT
cana-5045	101	3	10.3390	10.3390	NUM
cana-5045	101	4	/	/	SYM
cana-5045	101	5	ijms25042324	ijms25042324	PROPN
cana-5045	101	6	.	.	PUNCT
cana-5045	102	1	[	[	X
cana-5045	102	2	10	10	NUM
cana-5045	102	3	]	]	X
cana-5045	102	4	perucca	perucca	NOUN
cana-5045	102	5	,	,	PUNCT
cana-5045	102	6	emilio	emilio	PROPN
cana-5045	102	7	.	.	PUNCT
cana-5045	102	8	2012	2012	NUM
cana-5045	102	9	.	.	PUNCT
cana-5045	103	1	‘	'	PUNCT
cana-5045	103	2	what	what	PRON
cana-5045	103	3	clinical	clinical	ADJ
cana-5045	103	4	trial	trial	NOUN
cana-5045	103	5	designs	design	NOUN
cana-5045	103	6	have	have	AUX
cana-5045	103	7	been	be	AUX
cana-5045	103	8	used	use	VERB
cana-5045	103	9	to	to	PART
cana-5045	103	10	test	test	VERB
cana-5045	103	11	antiepileptic	antiepileptic	ADJ
cana-5045	103	12	drugs	drug	NOUN
cana-5045	103	13	and	and	CCONJ
cana-5045	103	14	do	do	AUX
cana-5045	103	15	we	we	PRON
cana-5045	103	16	need	need	VERB
cana-5045	103	17	to	to	PART
cana-5045	103	18	change	change	VERB
cana-5045	103	19	them	they	PRON
cana-5045	103	20	?	?	PUNCT
cana-5045	103	21	*	*	PUNCT
cana-5045	103	22	’	'	PUNCT
cana-5045	103	23	.	.	PUNCT
cana-5045	104	1	epileptic	epileptic	ADJ
cana-5045	104	2	disorders	disorder	NOUN
cana-5045	104	3	14(2):124–31	14(2):124–31	NUM
cana-5045	104	4	.	.	PUNCT
cana-5045	105	1	doi	doi	NOUN
cana-5045	105	2	:	:	PUNCT
cana-5045	105	3	10.1684	10.1684	NUM
cana-5045	105	4	/	/	SYM
cana-5045	105	5	epd.2012.0511	epd.2012.0511	NOUN
cana-5045	105	6	.	.	PUNCT
cana-5045	106	1	[	[	X
cana-5045	106	2	11	11	NUM
cana-5045	106	3	]	]	SYM
cana-5045	106	4	romoli	romoli	PROPN
cana-5045	106	5	,	,	PUNCT
cana-5045	106	6	michele	michele	PROPN
cana-5045	106	7	,	,	PUNCT
cana-5045	106	8	petra	petra	PROPN
cana-5045	106	9	mazzocchetti	mazzocchetti	PROPN
cana-5045	106	10	,	,	PUNCT
cana-5045	106	11	renato	renato	PROPN
cana-5045	106	12	d’alonzo	d’alonzo	PROPN
cana-5045	106	13	,	,	PUNCT
cana-5045	106	14	sabrina	sabrina	PROPN
cana-5045	106	15	siliquini	siliquini	PROPN
cana-5045	106	16	,	,	PUNCT
cana-5045	106	17	victoria	victoria	PROPN
cana-5045	106	18	elisa	elisa	PROPN
cana-5045	106	19	rinaldi	rinaldi	PROPN
cana-5045	106	20	,	,	PUNCT
cana-5045	106	21	alberto	alberto	PROPN
cana-5045	106	22	verrotti	verrotti	PROPN
cana-5045	106	23	,	,	PUNCT
cana-5045	106	24	paolo	paolo	NOUN
cana-5045	106	25	calabresi	calabresi	NOUN
cana-5045	106	26	,	,	PUNCT
cana-5045	106	27	and	and	CCONJ
cana-5045	106	28	cinzia	cinzia	PROPN
cana-5045	106	29	costa	costa	PROPN
cana-5045	106	30	.	.	PUNCT
cana-5045	107	1	2019	2019	NUM
cana-5045	107	2	.	.	PUNCT
cana-5045	108	1	‘	'	PUNCT
cana-5045	108	2	valproic	valproic	ADJ
cana-5045	108	3	acid	acid	NOUN
cana-5045	108	4	and	and	CCONJ
cana-5045	108	5	epilepsy	epilepsy	PROPN
cana-5045	108	6	:	:	PUNCT
cana-5045	108	7	from	from	ADP
cana-5045	108	8	molecular	molecular	ADJ
cana-5045	108	9	mechanisms	mechanism	NOUN
cana-5045	108	10	to	to	ADP
cana-5045	108	11	clinical	clinical	ADJ
cana-5045	108	12	evidences	evidence	NOUN
cana-5045	108	13	’	'	PUNCT
cana-5045	108	14	.	.	PUNCT
cana-5045	109	1	current	current	ADJ
cana-5045	109	2	neuropharmacology	neuropharmacology	NOUN
cana-5045	109	3	17(10):926–46	17(10):926–46	NOUN
cana-5045	109	4	.	.	PUNCT
cana-5045	110	1	doi	doi	NOUN
cana-5045	110	2	:	:	PUNCT
cana-5045	110	3	10.2174/1570159x17666181227165722	10.2174/1570159x17666181227165722	NUM
cana-5045	110	4	.	.	PUNCT
cana-5045	111	1	[	[	X
cana-5045	111	2	12	12	NUM
cana-5045	111	3	]	]	PUNCT
cana-5045	111	4	røste	røste	NOUN
cana-5045	111	5	,	,	PUNCT
cana-5045	111	6	l.	l.	PROPN
cana-5045	111	7	s.	s.	PROPN
cana-5045	111	8	,	,	PUNCT
cana-5045	111	9	e.	e.	PROPN
cana-5045	111	10	taubøll	taubøll	PROPN
cana-5045	111	11	,	,	PUNCT
cana-5045	111	12	l.	l.	PROPN
cana-5045	111	13	mørkrid	mørkrid	PROPN
cana-5045	111	14	,	,	PUNCT
cana-5045	111	15	t.	t.	PROPN
cana-5045	111	16	bjørnenak	bjørnenak	PROPN
cana-5045	111	17	,	,	PUNCT
cana-5045	111	18	e.	e.	PROPN
cana-5045	111	19	r.	r.	PROPN
cana-5045	111	20	sætre	sætre	PROPN
cana-5045	111	21	,	,	PUNCT
cana-5045	111	22	t.	t.	PROPN
cana-5045	111	23	mørland	mørland	PROPN
cana-5045	111	24	,	,	PUNCT
cana-5045	111	25	and	and	CCONJ
cana-5045	111	26	l.	l.	PROPN
cana-5045	111	27	gjerstad	gjerstad	PROPN
cana-5045	111	28	.	.	PUNCT
cana-5045	112	1	2005	2005	NUM
cana-5045	112	2	.	.	PUNCT
cana-5045	113	1	‘	'	PUNCT
cana-5045	113	2	antiepileptic	antiepileptic	ADJ
cana-5045	113	3	drugs	drug	NOUN
cana-5045	113	4	alter	alter	VERB
cana-5045	113	5	reproductive	reproductive	ADJ
cana-5045	113	6	endocrine	endocrine	NOUN
cana-5045	113	7	hormones	hormone	NOUN
cana-5045	113	8	in	in	ADP
cana-5045	113	9	men	man	NOUN
cana-5045	113	10	with	with	ADP
cana-5045	113	11	epilepsy	epilepsy	NOUN
cana-5045	113	12	’	'	PUNCT
cana-5045	113	13	.	.	PUNCT
cana-5045	114	1	european	european	PROPN
cana-5045	114	2	journal	journal	PROPN
cana-5045	114	3	of	of	ADP
cana-5045	114	4	neurology	neurology	NOUN
cana-5045	114	5	12(2):118–24	12(2):118–24	NUM
cana-5045	114	6	.	.	PUNCT
cana-5045	115	1	doi	doi	NOUN
cana-5045	115	2	:	:	PUNCT
cana-5045	115	3	10.1111	10.1111	NUM
cana-5045	115	4	/	/	SYM
cana-5045	115	5	j.1468	j.1468	NOUN
cana-5045	115	6	-	-	PUNCT
cana-5045	115	7	1331.2004.00899.x	1331.2004.00899.x	PROPN
cana-5045	115	8	.	.	PUNCT
cana-5045	116	1	[	[	X
cana-5045	116	2	13	13	NUM
cana-5045	116	3	]	]	PUNCT
cana-5045	116	4	røste	røste	NOUN
cana-5045	116	5	,	,	PUNCT
cana-5045	116	6	line	line	NOUN
cana-5045	116	7	sveberg	sveberg	PROPN
cana-5045	116	8	,	,	PUNCT
cana-5045	116	9	erik	erik	PROPN
cana-5045	116	10	taubøll	taubøll	ADV
cana-5045	116	11	,	,	PUNCT
cana-5045	116	12	aasmund	aasmund	PROPN
cana-5045	116	13	berner	berner	PROPN
cana-5045	116	14	,	,	PUNCT
cana-5045	116	15	kjell	kjell	PROPN
cana-5045	116	16	andersen	andersen	PROPN
cana-5045	116	17	berg	berg	PROPN
cana-5045	116	18	,	,	PUNCT
cana-5045	116	19	mona	mona	PROPN
cana-5045	116	20	aleksandersen	aleksandersen	PROPN
cana-5045	116	21	,	,	PUNCT
cana-5045	116	22	and	and	CCONJ
cana-5045	116	23	leif	leif	NOUN
cana-5045	116	24	gjerstad	gjerstad	NOUN
cana-5045	116	25	.	.	PUNCT
cana-5045	117	1	2001	2001	NUM
cana-5045	117	2	.	.	PUNCT
cana-5045	118	1	‘	'	PUNCT
cana-5045	118	2	morphological	morphological	ADJ
cana-5045	118	3	changes	change	NOUN
cana-5045	118	4	in	in	ADP
cana-5045	118	5	the	the	DET
cana-5045	118	6	testis	testis	NOUN
cana-5045	118	7	after	after	ADP
cana-5045	118	8	longterm	longterm	VERB
cana-5045	118	9	valproate	valproate	ADJ
cana-5045	118	10	treatment	treatment	NOUN
cana-5045	118	11	in	in	ADP
cana-5045	118	12	male	male	ADJ
cana-5045	118	13	wistar	wistar	PROPN
cana-5045	118	14	rats	rat	NOUN
cana-5045	118	15	’	'	PUNCT
cana-5045	118	16	.	.	PUNCT
cana-5045	119	1	seizure	seizure	VERB
cana-5045	119	2	10(8):559–65	10(8):559–65	NUM
cana-5045	119	3	.	.	PUNCT
cana-5045	120	1	doi	doi	NOUN
cana-5045	120	2	:	:	PUNCT
cana-5045	120	3	10.1053	10.1053	NUM
cana-5045	120	4	/	/	SYM
cana-5045	120	5	seiz.2001.0545	seiz.2001.0545	NUM
cana-5045	120	6	.	.	PUNCT
cana-5045	121	1	[	[	X
cana-5045	121	2	14	14	NUM
cana-5045	121	3	]	]	X
cana-5045	121	4	safdar	safdar	PROPN
cana-5045	121	5	,	,	PUNCT
cana-5045	121	6	ayesha	ayesha	PROPN
cana-5045	121	7	,	,	PUNCT
cana-5045	121	8	and	and	CCONJ
cana-5045	121	9	fatima	fatima	PROPN
cana-5045	121	10	ismail	ismail	PROPN
cana-5045	121	11	.	.	PUNCT
cana-5045	122	1	2023	2023	NUM
cana-5045	122	2	.	.	PUNCT
cana-5045	123	1	‘	'	PUNCT
cana-5045	123	2	a	a	DET
cana-5045	123	3	comprehensive	comprehensive	ADJ
cana-5045	123	4	review	review	NOUN
cana-5045	123	5	on	on	ADP
cana-5045	123	6	pharmacological	pharmacological	ADJ
cana-5045	123	7	applications	application	NOUN
cana-5045	123	8	and	and	CCONJ
cana-5045	123	9	drug	drug	NOUN
cana-5045	123	10	-	-	PUNCT
cana-5045	123	11	induced	induce	VERB
cana-5045	123	12	toxicity	toxicity	NOUN
cana-5045	123	13	of	of	ADP
cana-5045	123	14	valproic	valproic	ADJ
cana-5045	123	15	acid	acid	NOUN
cana-5045	123	16	’	'	PUNCT
cana-5045	123	17	.	.	PUNCT
cana-5045	124	1	saudi	saudi	ADJ
cana-5045	124	2	pharmaceutical	pharmaceutical	PROPN
cana-5045	124	3	journal	journal	PROPN
cana-5045	124	4	31(2):265–78	31(2):265–78	NUM
cana-5045	124	5	.	.	PUNCT
cana-5045	124	6	doi	doi	NOUN
cana-5045	124	7	:	:	PUNCT
cana-5045	124	8	10.1016	10.1016	NUM
cana-5045	124	9	/	/	SYM
cana-5045	124	10	j.jsps.2022.12.001	j.jsps.2022.12.001	PROPN
cana-5045	124	11	.	.	PUNCT
cana-5045	125	1	[	[	X
cana-5045	125	2	15	15	NUM
cana-5045	125	3	]	]	X
cana-5045	125	4	svalheim	svalheim	NOUN
cana-5045	125	5	,	,	PUNCT
cana-5045	125	6	sigrid	sigrid	VERB
cana-5045	125	7	,	,	PUNCT
cana-5045	125	8	line	line	NOUN
cana-5045	125	9	sveberg	sveberg	PROPN
cana-5045	125	10	,	,	PUNCT
cana-5045	125	11	monika	monika	PROPN
cana-5045	125	12	mochol	mochol	PROPN
cana-5045	125	13	,	,	PUNCT
cana-5045	125	14	and	and	CCONJ
cana-5045	125	15	erik	erik	PROPN
cana-5045	125	16	taubøll	taubøll	ADV
cana-5045	125	17	.	.	PUNCT
cana-5045	126	1	2015	2015	NUM
cana-5045	126	2	.	.	PUNCT
cana-5045	127	1	‘	'	PUNCT
cana-5045	127	2	interactions	interaction	NOUN
cana-5045	127	3	between	between	ADP
cana-5045	127	4	antiepileptic	antiepileptic	ADJ
cana-5045	127	5	drugs	drug	NOUN
cana-5045	127	6	and	and	CCONJ
cana-5045	127	7	hormones	hormone	NOUN
cana-5045	127	8	’	'	PUNCT
cana-5045	127	9	.	.	PUNCT
cana-5045	128	1	seizure	seizure	VERB
cana-5045	128	2	28:12–17	28:12–17	PROPN
cana-5045	128	3	.	.	PUNCT
cana-5045	129	1	doi	doi	NOUN
cana-5045	129	2	:	:	PUNCT
cana-5045	129	3	10.1016	10.1016	NUM
cana-5045	129	4	/	/	SYM
cana-5045	129	5	j.seizure.2015.02.022	j.seizure.2015.02.022	NOUN
cana-5045	129	6	.	.	PUNCT
cana-5045	130	1	[	[	X
cana-5045	130	2	16	16	NUM
cana-5045	130	3	]	]	PUNCT
cana-5045	130	4	tallon	tallon	PROPN
cana-5045	130	5	,	,	PUNCT
cana-5045	130	6	eva	eva	PROPN
cana-5045	130	7	,	,	PUNCT
cana-5045	130	8	louise	louise	PROPN
cana-5045	130	9	o’donovan	o’donovan	PROPN
cana-5045	130	10	,	,	PUNCT
cana-5045	130	11	and	and	CCONJ
cana-5045	130	12	norman	norman	PROPN
cana-5045	130	13	delanty	delanty	PROPN
cana-5045	130	14	.	.	PUNCT
cana-5045	130	15	2021	2021	NUM
cana-5045	130	16	.	.	PUNCT
cana-5045	131	1	‘	'	PUNCT
cana-5045	131	2	reversible	reversible	ADJ
cana-5045	131	3	male	male	ADJ
cana-5045	131	4	infertility	infertility	NOUN
cana-5045	131	5	with	with	ADP
cana-5045	131	6	valproate	valproate	ADJ
cana-5045	131	7	use	use	NOUN
cana-5045	131	8	:	:	PUNCT
cana-5045	131	9	a	a	DET
cana-5045	131	10	review	review	NOUN
cana-5045	131	11	of	of	ADP
cana-5045	131	12	the	the	DET
cana-5045	131	13	literature	literature	NOUN
cana-5045	131	14	’	'	PUNCT
cana-5045	131	15	.	.	PUNCT
cana-5045	132	1	epilepsy	epilepsy	PROPN
cana-5045	132	2	&	&	CCONJ
cana-5045	132	3	behavior	behavior	NOUN
cana-5045	132	4	reports	report	VERB
cana-5045	132	5	16:100446	16:100446	NUM
cana-5045	132	6	.	.	PUNCT
cana-5045	132	7	doi	doi	NOUN
cana-5045	132	8	:	:	PUNCT
cana-5045	133	1	10.1016	10.1016	NUM
cana-5045	133	2	/	/	SYM
cana-5045	133	3	j.ebr.2021.100446	j.ebr.2021.100446	PROPN
cana-5045	133	4	.	.	PUNCT
cana-5045	134	1	[	[	X
cana-5045	134	2	17	17	NUM
cana-5045	134	3	]	]	X
cana-5045	134	4	trivedi	trivedi	NOUN
cana-5045	134	5	,	,	PUNCT
cana-5045	134	6	p.	p.	PROPN
cana-5045	134	7	p.	p.	PROPN
cana-5045	134	8	,	,	PUNCT
cana-5045	134	9	s.	s.	PROPN
cana-5045	134	10	kushwaha	kushwaha	PROPN
cana-5045	134	11	,	,	PUNCT
cana-5045	134	12	d.	d.	PROPN
cana-5045	134	13	n.	n.	PROPN
cana-5045	134	14	tripathi	tripathi	PROPN
cana-5045	134	15	,	,	PUNCT
cana-5045	134	16	and	and	CCONJ
cana-5045	134	17	g.	g.	PROPN
cana-5045	134	18	b.	b.	PROPN
cana-5045	134	19	jena	jena	PROPN
cana-5045	134	20	.	.	PUNCT
cana-5045	135	1	2010	2010	NUM
cana-5045	135	2	.	.	PUNCT
cana-5045	136	1	‘	'	PUNCT
cana-5045	136	2	evaluation	evaluation	NOUN
cana-5045	136	3	of	of	ADP
cana-5045	136	4	male	male	ADJ
cana-5045	136	5	germ	germ	NOUN
cana-5045	136	6	cell	cell	NOUN
cana-5045	136	7	toxicity	toxicity	NOUN
cana-5045	136	8	in	in	ADP
cana-5045	136	9	rats	rat	NOUN
cana-5045	136	10	:	:	PUNCT
cana-5045	136	11	correlation	correlation	NOUN
cana-5045	136	12	between	between	ADP
cana-5045	136	13	sperm	sperm	NOUN
cana-5045	136	14	head	head	NOUN
cana-5045	136	15	morphology	morphology	NOUN
cana-5045	136	16	and	and	CCONJ
cana-5045	136	17	sperm	sperm	NOUN
cana-5045	136	18	comet	comet	NOUN
cana-5045	136	19	assay	assay	VERB
cana-5045	136	20	’	'	PUNCT
cana-5045	136	21	.	.	PUNCT
cana-5045	137	1	mutation	mutation	NOUN
cana-5045	137	2	research	research	NOUN
cana-5045	137	3	/	/	SYM
cana-5045	137	4	genetic	genetic	ADJ
cana-5045	137	5	toxicology	toxicology	NOUN
cana-5045	137	6	and	and	CCONJ
cana-5045	137	7	environmental	environmental	ADJ
cana-5045	137	8	mutagenesis	mutagenesis	NOUN
cana-5045	137	9	703(2):115–21	703(2):115–21	NUM
cana-5045	137	10	.	.	PUNCT
cana-5045	138	1	doi	doi	NOUN
cana-5045	138	2	:	:	PUNCT
cana-5045	138	3	10.1016	10.1016	NUM
cana-5045	138	4	/	/	SYM
cana-5045	138	5	j.mrgentox.2010.08.005	j.mrgentox.2010.08.005	PROPN
cana-5045	138	6	.	.	PUNCT
cana-5045	139	1	[	[	X
cana-5045	139	2	18	18	NUM
cana-5045	139	3	]	]	PUNCT
cana-5045	139	4	vijay	vijay	NOUN
cana-5045	139	5	,	,	PUNCT
cana-5045	139	6	p.	p.	PROPN
cana-5045	139	7	,	,	PUNCT
cana-5045	139	8	r.	r.	PROPN
cana-5045	139	9	yeshwanth	yeshwanth	PROPN
cana-5045	139	10	,	,	PUNCT
cana-5045	139	11	and	and	CCONJ
cana-5045	139	12	kl	kl	PROPN
cana-5045	139	13	bairy	bairy	PROPN
cana-5045	139	14	.	.	PUNCT
cana-5045	139	15	2008	2008	NUM
cana-5045	139	16	.	.	PUNCT
cana-5045	140	1	‘	'	PUNCT
cana-5045	140	2	the	the	DET
cana-5045	140	3	effect	effect	NOUN
cana-5045	140	4	of	of	ADP
cana-5045	140	5	sodium	sodium	NOUN
cana-5045	140	6	valproate	valproate	ADJ
cana-5045	140	7	on	on	ADP
cana-5045	140	8	the	the	DET
cana-5045	140	9	biochemical	biochemical	ADJ
cana-5045	140	10	parameters	parameter	NOUN
cana-5045	140	11	of	of	ADP
cana-5045	140	12	reproductive	reproductive	ADJ
cana-5045	140	13	function	function	NOUN
cana-5045	140	14	in	in	ADP
cana-5045	140	15	male	male	ADJ
cana-5045	140	16	albino	albino	NOUN
cana-5045	140	17	wistar	wistar	PROPN
cana-5045	140	18	rats	rat	NOUN
cana-5045	140	19	’	'	PUNCT
cana-5045	140	20	.	.	PUNCT
cana-5045	141	1	indian	indian	PROPN
cana-5045	141	2	journal	journal	PROPN
cana-5045	141	3	of	of	ADP
cana-5045	141	4	pharmacology	pharmacology	NOUN
cana-5045	141	5	40(6):248	40(6):248	NOUN
cana-5045	141	6	.	.	PUNCT
cana-5045	142	1	doi	doi	NOUN
cana-5045	142	2	:	:	PUNCT
cana-5045	142	3	10.4103/0253	10.4103/0253	NUM
cana-5045	142	4	-	-	SYM
cana-5045	142	5	7613.45149	7613.45149	NOUN
cana-5045	142	6	.	.	PUNCT
cana-5045	143	1	[	[	X
cana-5045	143	2	19	19	NUM
cana-5045	143	3	]	]	X
cana-5045	143	4	walke	walke	PROPN
cana-5045	143	5	,	,	PUNCT
cana-5045	143	6	gireeja	gireeja	PROPN
cana-5045	143	7	,	,	PUNCT
cana-5045	143	8	sagar	sagar	PROPN
cana-5045	143	9	s.	s.	PROPN
cana-5045	143	10	gaurkar	gaurkar	PROPN
cana-5045	143	11	,	,	PUNCT
cana-5045	143	12	roshan	roshan	PROPN
cana-5045	143	13	prasad	prasad	PROPN
cana-5045	143	14	,	,	PUNCT
cana-5045	143	15	tejaswee	tejaswee	NOUN
cana-5045	143	16	lohakare	lohakare	NOUN
cana-5045	143	17	,	,	PUNCT
cana-5045	143	18	and	and	CCONJ
cana-5045	143	19	mayur	mayur	PROPN
cana-5045	143	20	wanjari	wanjari	PROPN
cana-5045	143	21	.	.	PUNCT
cana-5045	144	1	2023	2023	NUM
cana-5045	144	2	.	.	PUNCT
cana-5045	145	1	‘	'	PUNCT
cana-5045	145	2	the	the	DET
cana-5045	145	3	impact	impact	NOUN
cana-5045	145	4	of	of	ADP
cana-5045	145	5	oxidative	oxidative	ADJ
cana-5045	145	6	stress	stress	NOUN
cana-5045	145	7	on	on	ADP
cana-5045	145	8	male	male	ADJ
cana-5045	145	9	reproductive	reproductive	ADJ
cana-5045	145	10	function	function	NOUN
cana-5045	145	11	:	:	PUNCT
cana-5045	145	12	exploring	explore	VERB
cana-5045	145	13	the	the	DET
cana-5045	145	14	role	role	NOUN
cana-5045	145	15	of	of	ADP
cana-5045	145	16	antioxidant	antioxidant	ADJ
cana-5045	145	17	supplementation	supplementation	NOUN
cana-5045	145	18	’	'	PUNCT
cana-5045	145	19	.	.	PUNCT
cana-5045	146	1	cureus	cureus	NOUN
cana-5045	146	2	.	.	PUNCT
cana-5045	147	1	doi	doi	NOUN
cana-5045	147	2	:	:	PUNCT
cana-5045	147	3	10.7759	10.7759	NUM
cana-5045	147	4	/	/	SYM
cana-5045	147	5	cureus.42583	cureus.42583	PROPN
cana-5045	147	6	.	.	PUNCT